Constitutively active PYR/PYL receptor proteins for improving plant stress tolerance

ABSTRACT

The present invention provides methods of regulating plant stress tolerance.

CROSS-REFERENCE TO RELATED PATENT APPLICATIONS

This application is a divisional of application Ser. No. 12/705,413, filed Feb. 12, 2010, which claims the benefit of U.S. Provisional Patent Application No. 61/207,684, filed Feb. 13, 2009, each of which is incorporated by reference for all purposes.

REFERENCE TO A “SEQUENCE LISTING,” A TABLE, OR A COMPUTER PROGRAM LISTING APPENDIX SUBMITTED AS AN ASCII TEXT FILE

The Sequence Listing written in file-1954-3.TXT, created on Jun. 3, 2014, 233,472 bytes, machine format IBM-PC, MS-Windows operating system, is hereby incorporated by reference in its entirety for all purposes.

BACKGROUND OF THE INVENTION

Abscisic acid (ABA) has been the focus of intense investigation since it was identified in the 1960s as an endogenous small molecule growth inhibitor and regulator of plant stress physiology (K. Ohkuma, J. L. Lyon, F. T. Addicott, O. E. Smith, Science 142, 1592 (1963); C. F. Eagles, P. E. Wareing, Physiologia Plantarum 17, 697 (1964); J. W. Cornforth, B. V. Milborrow, G. Ryback, Nature 206, 715 (1965); J. W. Cornforth, B. V. Milborrow, G. Ryback, P. F. Wareing, Nature 205, 1269 (1965); D. Imber, M. Tal, Science 169 592 (1970)). Indeed, when one increases plant ABA sensitivity, improved drought and other stress tolerance results. See, e.g. Wang et al., Plant J. 43:413-424 (2005); Pei et al. Science 282:287-290 (1998); US Patent Publication No 2004/0010821. Genetic analyses have identified many factors involved in ABA signaling, including the type 2 C protein phosphatases (PP2Cs) ABI1, ABI2 and relatives that form the closely related ABI1/AHG1 clades that function as redundant negative regulators of ABA signaling (R. R. Finkelstein, S. S. L. Gampala, C. D. Rock, The Plant Cell 14, S15 (2002); P. McCourt, Annual Review of Plant Physiology and Plant Molecular Biology 50, 219 (1999); A. Schweighofer, H. Hirt, I. Meskiene, Trends in Plant Science 9, 236 (2004)). Several ABA binding proteins have been reported, however it is not clear how they regulate the myriad effects of ABA, because they do not appear to act through known regulators of its signaling pathway (X. Liu et al., Science 315, 1712 (Mar. 23, 2007); F. A. Razem, A. El-Kereamy, S. R. Abrams, R. D. Hill, Nature 439, 290 (2006); Y. Y. Shen et al., Nature 443, 823 (Oct. 19, 2006)). Additionally, the characterized receptors show negligible binding to the non-natural stereoisomer (−)-ABA 1 at concentrations ˜1000-fold higher than their K_(d)s for (+)-ABA 2. (−)-ABA is bioactive in most ABA assays (B.-L. Lin, H.-J. Wang, J.-S. Wang, L. I. Zaharia, S. R. Abrams, Journal of Experimental Botany 56, 2935 (2005); D. Huang et al., The Plant Journal 50, 414 (2007)) and acts through the same signaling pathway as (+)-ABA (E. Nambara et al., Genetics 161, 1247 (July, 2002)), suggesting that receptors that recognize both (−) and (+)-ABA remain to be discovered.

BRIEF SUMMARY OF THE INVENTION

The present invention provides for plants (or a plant cell, seed, flower, leaf, fruit, or other plant part from such plants) comprising a heterologous expression cassette, the expression cassette comprising a promoter operably linked to a polynucleotide encoding a PYR/PYL receptor polypeptide, wherein the plant has improved stress tolerance compared to a plant lacking the expression cassette.

In some embodiments, the PYR/PYL receptor polypeptide comprises one or more of SEQ ID NOs:1, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107 and/or 138.

In some embodiments, the PYR/PYL receptor polypeptide is at least 70% (e.g., at least 70%, 80%, 90%, 95%) identical to any of SEQ ID NOs:2-90 or 108-137.

In some embodiments, the PYR/PYL receptor polypeptide is a constitutively-active form such that the receptor will bind a type 2 protein phosphatase (PP2C) in a yeast two-hybrid assay in the absence of abscisic acid or an ABA agonist.

In some embodiments, the PYR/PYL receptor polypeptide bind a type 2 protein phosphatase (PP2C) in a yeast two-hybrid assay in the presence, but not in the absence, of abscisic acid or an ABA agonist.

In some embodiments, the plant has improved drought tolerance compared to a plant lacking the expression cassette.

In some embodiments, the promoter is a root-specific promoter.

In some embodiments, the promoter is specific for an aerial portion of the plant.

In some embodiments, the promoter is inducible.

The present invention also provides for methods of increasing stress tolerance in a plant as described above. In some embodiments, the method comprises contacting the plant with a sufficient amount of a compound to increase stress tolerance compared to not contacting the plant with the compound, wherein the compound is selected from the following formulas:

-   -   wherein

R¹ is selected from the group consisting of aryl and heteroaryl, optionally substituted with 1-3 R^(1a) groups;

each R^(1a) is independently selected from the group consisting of H, halogen, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ alkoxy, C₁₋₆ haloalkoxy, C₁₋₆ hydroxyalkyl, —NR′R″, —SR′, —OH, —CN, —NO₂, —C(O)R′, —C(O)OR′, —C(O)NR′R″, —N(R′)C(O)R″, —N(R′)C(O)OR″, —N(R′)C(O)NR′R″, —OP(O)(OR′)₂, —S(O)₂OR′, —S(O)₂NR′R″, cycloalkyl, heterocycloalkyl, aryl and heteroaryl, wherein the aryl group is optionally substituted with —NO₂ and the heteroaryl group is optionally substituted with C₁₋₆ alkyl;

alternatively, adjacent R^(1a) groups can combine to form a member selected from the group consisting of cycloalkyl, heterocycloalkyl, aryl and heteroaryl, wherein the aryl group is optionally substituted with —OH;

R′ and R″ are each independently selected from the group consisting of H and C₁₋₆ alkyl;

R² is selected from the group consisting of C₂₋₆ alkenyl, cycloalkenyl, aryl and heteroaryl;

R³ is H or is optionally combined with R² and the atoms to which each is attached to form a heterocycloalkyl optionally substituted with 1-3 R^(1a) groups;

R⁴ is a heteroaryl, optionally substituted with 1-3 R^(1a) groups;

R⁵ is selected from the group consisting of C₁₋₆ alkyl and aryl, wherein the aryl is optionally substituted with 1-3 R^(1a) groups;

each of R⁶ and R⁷ are independently selected from the group consisting of aryl and heteroaryl, each optionally substituted with 1-3 R^(1a) groups;

R⁸ is selected from the group consisting of cycloalkyl and aryl, each optionally substituted with 1-3 R^(1a) groups;

R⁹ is H or is optionally combined with a R^(1a) group of R⁸ and the atoms to which each is attached to form a heterocycloalkyl; subscript n is 0-2;

X is absent or is selected from the group consisting of —O—, and —N(R′)—;

Y is absent or is selected from the group consisting of —C(O)— and —C(R′,R″)—;

Z is absent or is selected from the group consisting of —N═, and —C(S)—N(R′)—, such that one of Y and Z is absent;

each of R¹⁰ and R¹¹ are independently selected from the group consisting of H, C₁₋₆ alkyl, —C(O)OR′, and C₁₋₆ alkenyl-C(O)OH, wherein at least two of the R¹⁰ and R¹¹ groups are C₁₋₆ alkyl and at least one of the R¹⁰ and R¹¹ groups is C₁₋₆ alkenyl-C(O)OH;

alternatively, two R¹⁰ or R¹¹ groups attached to the same carbon are combined to form ═O;

alternatively, one R¹⁰ group and one R¹¹ group are combined to form a cycloalkyl having from 3 to 6 ring members;

each of subscripts k and m is an integer from 1 to 3, such that the sum of k and m is from 3 to 4;

each of subscripts p and r is an integer from 1 to 10;

wherein two of the R¹⁰ and R¹¹ groups on adjacent carbons are combined to form a bond;

R¹² is a C₁₋₆ alkyl, substituted with a ═O;

R¹³ is C₁₋₆ alkenyl-C(O)OH;

R¹⁴ is selected from the group consisting of H and C₁₋₆ alkyl; and

subscript r is an integer from 1 to 10;

with the proviso that when R¹ is 4-bromo-naphthalen-1-yl, and n is 1, R² is other than unsubstituted pyrid-2-yl

The present invention also provides an expression cassette comprising a promoter operably linked to a polynucleotide encoding a PYR/PYL receptor polypeptide, wherein introduction of the expression cassette into a plant results in the plant having improved stress tolerance compared to a plant lacking the expression cassette.

In some embodiments, the PYR/PYL receptor polypeptide comprises one or more of SEQ ID NOs:1, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107 and/or 138.

In some embodiments, the PYR/PYL receptor polypeptide is at least 70% (e.g., at least 70%, 80%, 90%, 95%) identical to any of SEQ ID NOs:2-90 or 108-137.

In some embodiments, the PYR/PYL receptor polypeptide is a constitutively-active form such that the receptor will bind a type 2 protein phosphatase (PP2C) in a yeast two-hybrid assay in the absence of abscisic acid or an ABA agonist.

In some embodiments, the PYR/PYL receptor polypeptide bind a type 2 protein phosphatase (PP2C) in a yeast two-hybrid assay in the presence, but not in the absence, of abscisic acid or an ABA agonist.

In some embodiments, the plant has improved drought tolerance compared to a plant lacking the expression cassette.

In some embodiments, the promoter is a root-specific promoter. In some embodiments, the promoter is specific for an aerial portion of the plant. In some embodiments, the promoter is inducible.

The present invention also provides for expression vectors comprising an expression cassette of the invention (e.g., as described above).

The present invention also provides for methods of making a plant with increased stress tolerance. In some embodiments, the method comprises:

introducing the an expression cassette of the invention (e.g., as described above) into a plurality of plants; and

selecting a plant comprising the expression cassette having increased stress tolerance compared to a plant lacking the expression cassette.

The present invention also provides an agricultural chemical formulation formulated for contacting to plants, the formulation comprising a compound selected from the following formulas:

-   -   wherein

R¹ is selected from the group consisting of aryl and heteroaryl, optionally substituted with 1-3 R^(1a) groups;

each R^(1a) is independently selected from the group consisting of H, halogen, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ alkoxy, C₁₋₆ haloalkoxy, C₁₋₆ hydroxyalkyl, —NR′R″, —SR′, —OH, —CN, —NO₂, —C(O)R′, —C(O)OR′, —C(O)NR′R″, —N(R′)C(O)R″, —N(R′)C(O)OR″, —N(R′)C(O)NR′R″, —OP(O)(OR′)₂, —S(O)₂OR′, —S(O)₂NR′R″, cycloalkyl, heterocycloalkyl, aryl and heteroaryl, wherein the aryl group is optionally substituted with —NO₂ and the heteroaryl group is optionally substituted with C₁₋₆ alkyl;

alternatively, adjacent R^(1a) groups can combine to form a member selected from the group consisting of cycloalkyl, heterocycloalkyl, aryl and heteroaryl, wherein the aryl group is optionally substituted with —OH;

R′ and R″ are each independently selected from the group consisting of H and C₁₋₆ alkyl;

R² is selected from the group consisting of C₂₋₆ alkenyl, cycloalkenyl, aryl and heteroaryl;

R³ is H or is optionally combined with R² and the atoms to which each is attached to form a heterocycloalkyl optionally substituted with 1-3 R^(1a) groups;

R⁴ is a heteroaryl, optionally substituted with 1-3 R^(1a) groups;

R⁵ is selected from the group consisting of C₁₋₆ alkyl and aryl, wherein the aryl is optionally substituted with 1-3 R^(1a) groups;

each of R⁶ and R⁷ are independently selected from the group consisting of aryl and heteroaryl, each optionally substituted with 1-3 R^(1a) groups;

R⁸ is selected from the group consisting of cycloalkyl and aryl, each optionally substituted with 1-3 R^(1a) groups;

R⁹ is H or is optionally combined with a R^(1a) group of R⁸ and the atoms to which each is attached to form a heterocycloalkyl; subscript n is 0-2;

X is absent or is selected from the group consisting of —O—, and —N(R′)—;

Y is absent or is selected from the group consisting of —C(O)— and —C(R′,R″)—;

Z is absent or is selected from the group consisting of —N═, and —C(S)—N(R′)—, such that one of Y and Z is absent;

each of R¹⁰ and R¹¹ are independently selected from the group consisting of H, C₁₋₆ alkyl, —C(O)OR′, and C₁₋₆ alkenyl-C(O)OH, wherein at least two of the R¹⁰ and R¹¹ groups are C₁₋₆ alkyl and at least one of the R¹⁰ and R¹¹ groups is C₁₋₆ alkenyl-C(O)OH;

alternatively, two R¹⁰ or R¹¹ groups attached to the same carbon are combined to form ═O;

alternatively, one R¹⁰ group and one R¹¹ group are combined to form a cycloalkyl having from 3 to 6 ring members;

each of subscripts k and m is an integer from 1 to 3, such that the sum of k and m is from 3 to 4;

each of subscripts p and r is an integer from 1 to 10;

wherein two of the R¹⁰ and R¹¹ groups on adjacent carbons are combined to form a bond;

R¹² is a C₁₋₆ alkyl, substituted with a ═O;

R¹³ is C₁₋₆ alkenyl-C(O)OH;

R¹⁴ is selected from the group consisting of H and C₁₋₆ alkyl; and

subscript r is an integer from 1 to 10;

with the proviso that when R¹ is 4-bromo-naphthalen-1-yl, and n is 1, R² is other than unsubstituted pyrid-2-yl

In some embodiments, the formulation further comprises at least one of an herbicide, fungicide, pesticide, or fertilizer. In some embodiments, the formulation further comprises a surfactant.

The present invention also provides for a method of increasing stress tolerance in a plant, the method comprising contacting a plant with a sufficient amount of a formulation as described above to increase stress tolerance in the plant compared to not contacting the plant with the compound.

In some embodiments, the contacting step comprises delivering the formulation to the plant by aircraft or irrigation.

The present invention also provides for a method of identifying an agent that agonizes a PYR/PYL polypeptide. In some embodiments, the method comprises

contacting one or more agents to a PYR/PYL polypeptide; and

determining whether the one or more agents bind to and/or or activate the PYR/PYL receptor polypeptide, wherein binding or activation identifies the agent as an agonist of the PYR/PYL polypeptide.

In some embodiments, the determining step comprises contacting the agent to a cell comprising a two-hybrid system, wherein the two-hybrid systems detects interaction of the PYR/PYL polypeptide to a type 2 protein phosphatase (PP2C), wherein agent-dependent interaction of the PYR/PYL polypeptide to the PP2C identifies the agent as an agonist of the PYR/PYL polypeptide.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1. Pyrabactin is a seed selective ABA agonist. (A) Structures of molecules described in this study. (B) Pyrabactin activity is suppressed by abi1-1. Seeds of the genotype shown at top were imbibed on media containing 25 μM pyrabactin and scored for germination 4 days after stratification. Shown at bottom are IC₅₀ values for pyrabactin's germination effect on the genotypes characterized. (C) Microarray comparison of pyrabactin and ABA treatments in seeds. The Y-axis plots the log₂ transformed value for a probe's response to 25 μM pyrabactin (relative to untreated control) and the X-axis a probe's response to 1 μM ABA. Plotted are data for probe sets that showed significant responsiveness to ABA or pyrabactin, after removing germination responsive transcripts. (D) Microarray comparison of cycloheximide and ABA responses in seeds. This plot shows the response of the same probe sets analyzed in panel C, but the comparisons are to mRNAs from cycloheximide treated seeds (y-axis). (E) Microarray comparison of pyrabactin and ABA responses in seedlings. Seven-day old seedlings were transferred to 10 μM ABA or 50 μM pyrabactin containing plates for 24 hours and then mRNA samples profiled. Inset in each scatter plot is the Pearson correlation coefficient for each comparison. Detailed microarray methods are described in the Examples section.

FIG. 2. PYR1 encodes an ABA responsive START-domain protein. (A) Pyr1 alleles. Shown are the allele names, strain names (in parentheses) and amino acid changes caused by the Pyr1 mutant alleles identified by screening for pyrabactin resistant mutations. (B) Pictographic representation of Pyr1 and Pyl1-Pyl4 expression values housed in public microarray databases. The heatmap shown at top right is for the first upper three panels and the bottom heatmap for the guard cell data. Plots were made using the eFP browser (D. Winter et al., PLoS ONE 2, e718 (2007)). (C) 35S::GFP-PYR1 complements pyr1-1. Seeds of the genotypes shown were stratified 4 days on 25 μM pyrabactin and then germinated at RT, 90% RH for 3 days in darkness. The Columbia wild type is unable to germinate under these conditions, but pyr1-1 does because it is resistant to pyrabactin. Introduction of a 35S::GFP-PYR1 construct into the pyr1-1 genetic background restores pyrabactin sensitivity, which indicates that the GFP fusion protein is functional. (D) Pyr/Pyls are required for normal ABA-induced gene expression in seedlings. Shown are qRT-PCR results for the ABA-responsive gene RD29. L, Ler; C, Col; and Q, quadruple mutant. (E) Pyr/Pyl genes are required for normal ABA-induced stress-induced gene expression in seedlings. Shown are qRT-PCR results for two ABA-responsive taqman probes, as described in the Examples section. L=Ler, C=Col, Q=quadruple mutant.

FIG. 3. ABA promotes PYR/PYL binding to PP2Cs. (A) Characterization of the PYR/PYL protein interactions with HAB1. Shown are X-gal stains of yeast colonies grown on plates containing the compounds shown at top. The Arabidopsis Genome Initiative (AGI) annotations for each PYR/PYL gene characterized is shown at the right of the panel. Not tested were PYL8 (AT5G53160) and PYL13 (AT4G18620). Each strain tested expresses an AD-HAB1 fusion protein and the BD-fusion shown at left. Chemicals were tested at 10 μM with the exception of epi-brassinolide (50 nM). (B) PYR1 mutant proteins are defective in their interactions with HAB1. 3 PYR1 amino acid substitution mutants that display strong pyrabactin insensitivity in Arabidopsis seeds were tested for their interactions with HAB1 in the Y2H. (C) PYR1 interacts with ABI1 and ABI2 but not the mutant protein encoded by abi2-1.

FIG. 4. GFP-PYR1 localizes to the cytoplasm and nucleoplasm. Confocal images are shown of a 35S::GFP-PYR1 construct in the pyr1-1 mutant background. This construct complements the pyrabactin insensitivity phenotype of the pyr1-1 mutant.

FIG. 5. Pyr1 and Pyl1, 2 and 4 function redundantly in ABA perception. (A) ABA responses in the triple and quadruple mutant lines are altered during germination. Seeds of the genotypes shown at top were stratified 4 days on media containing 0.9 μM (+)-ABA and then photographed 3 days after germination in darkness. The short hypocotyl observed in the quadruple mutant when germinated on (+)-ABA is due to the presence of the erecta mutation that is tightly linked to the pyl2-1 insertion allele. (B) ABA responses in the triple and quadruple mutant lines are altered during root growth. Seeds of the genotypes shown at top were stratified 4 days and then transferred to darkness (RT, 90% RH). After 30 hours, seeds with radicle emergence were transferred to plates contain 10 μM (+)-ABA and their roots photographed after an additional 3 days growth in the dark.

FIG. 6. PYR1 is an ABA receptor that regulates PP2C activity. (A) Reconstitution of ABA perception in vitro. Pull-down assays using GST-HAB1 and 6×His-PYR1 (or mutants) were conducted using purified recombinant proteins (left panel). GST-ABI1 and ABI2 were additionally tested in pull-downs using purified 6×His-PYR1 (or mutants) and crude lysates containing the PP2Cs shown. 10 μM (+)-ABA was used. (B) PYR1 inhibits PP2C activity in the presence of ABA. The PP2C activity of GST-HAB1 was tested in the presence or PYR1 or PYR1^(P88S) at different concentrations of ABA using the substrate pNPP. (C) ABA/PYL4-dependent inhibition of HAR1 PP2C activity. Recombinant PYL4 (refolded from inclusion bodies) and HAB1 were used in PP2C assays as described. Activity was measured for GST-HAB1 using the phosphatase substrate pNPP. Phosphatase initial reaction velocities were calculated in triplicate by monitoring reactions over time using a plate reader in triplicate and used to calculate activities. The top panel shows the full concentration ranged studied; bottom panel a zoomed region of the lower concentrations tested. The specific activity of the GST-HAB1 used in these experiments was 452.4±12.3 μmol/min/mg. Points plotted use ±SD as error bars.

FIG. 7. Proposed model for PYR/PYL control of ABA signaling. Without intending to limit the scope of the invention, we propose the following model: In the absence of ABA (left), PYR/PYL proteins show low binding to PP2Cs, and therefore, PP2C activity is high, which prevents phosphorylation and activation of SnRK2s and downstream factors (DFs). In the presence of ABA, PYR/PYLs bind and inhibit PP2Cs. This allows accumulation of phosphorylated downstream factors and ABA transcriptional responses. The regulation of SnRK2s by PYR/PYLs may be indirect or may involve other factors.

FIG. 8. Activity of small molecule ABA agonists. This figure summarizes data from screening small molecules for receptor activity of PYR1, PYL1, PYL2, PYL3, and PYL4.

FIG. 9. IC50 values for some compounds identified in the PP2C yeast two-hybrid assay. Compound numbers listed in left column correspond to compounds identified in the assay summarized in FIG. 9. Compound 7653159 corresponds to compound 7 in FIG. 9; compound 6655097 corresponds to compound 6 in FIG. 9; and compound 7561035 corresponds to compound 9 in FIG. 9. For each compound, the ability of the compound to agonize PYR/PYL inhibition of the PP2C HAB1 was assessed using a phosphatase assay with the phosphatase substrate pNPP.

FIG. 10. Table of ABA-related phenotypes in the PYL4 overexpression line. PYL4-overexpressing and pyr1; pyl1; pyl2; pyl4 quadruple mutant Arabidopsis plants were examined for changes in stress response associated traits including flowering time, stature, chlorophyll content, and wiltiness relative to control Arabidopsis plants. Full details for the construction of the mutant plants are provided in the Examples section.

FIG. 11. Alignment of PYR1 and homologs from Arabidopsis. (A)-(E) An alignment of Arabidopsis PYR/PYL protein sequences is provided. The alignment displays, for example, absolutely conserved amino acids as well as amino acids at positions that are typically conserved. Sequences in the figure include the following PYR/PYL polypeptides: PYL12 (SEQ ID NO:77), PYL8 (SEQ ID NO:78), PYL7 (SEQ ID NO:79), PYL9 (SEQ ID NO:80), PYL11 (SEQ ID NO:81) PYL10 (SEQ ID NO:82), PYL13 (SEQ ID NO:83), PYL5 (SEQ ID NO:84), PYL4 (SEQ ID NO:85), PYL6 (SEQ ID NO:86), PYL2 (SEQ ID NO:87), PYL3 (SEQ ID NO:88), PYR1 (SEQ ID NO:89), and PYL1 (SEQ ID NO:90). Consensus sequences derived from specified members are set forth below the alignment. ALL_Con=SEQ ID NOS:93-95; 1_12_Con=SEQ ID NOS:96-99; 1_6_Con=SEQ ID NOS:100, 139 and 102; 7_10_Con=SEQ ID NOS:103 and 140; 11_13_Con=SEQ ID NOS:106 and 107.

FIG. 12. Activity of additional ABA agonists. The listed compounds include the naturally-occurring plant compound artemisinic acid, as well as analogs thereof.

DEFINITIONS

The term “promoter,” as used herein, refers to a polynucleotide sequence capable of driving transcription of a coding sequence in a cell. Thus, promoters used in the polynucleotide constructs of the invention include cis-acting transcriptional control elements and regulatory sequences that are involved in regulating or modulating the timing and/or rate of transcription of a gene. For example, a promoter can be a cis-acting transcriptional control element, including an enhancer, a promoter, a transcription terminator, an origin of replication, a chromosomal integration sequence, 5′ and 3′ untranslated regions, or an intronic sequence, which are involved in transcriptional regulation. These cis-acting sequences typically interact with proteins or other biomolecules to carry out (turn on/off, regulate, modulate, etc.) gene transcription. A “plant promoter” is a promoter capable of initiating transcription in plant cells. A “constitutive promoter” is one that is capable of initiating transcription in nearly all tissue types, whereas a “tissue-specific promoter” initiates transcription only in one or a few particular tissue types.

The term “plant” includes whole plants, shoot vegetative organs and/or structures (e.g., leaves, stems and tubers), roots, flowers and floral organs (e.g., bracts, sepals, petals, stamens, carpels, anthers), ovules (including egg and central cells), seed (including zygote, embryo, endosperm, and seed coat), fruit (e.g., the mature ovary), seedlings, plant tissue (e.g., vascular tissue, ground tissue, and the like), cells (e.g., guard cells, egg cells, trichomes and the like), and progeny of same. The class of plants that can be used in the method of the invention is generally as broad as the class of higher and lower plants amenable to transformation techniques, including angiosperms (monocotyledonous and dicotyledonous plants), gymnosperms, ferns, and multicellular algae. It includes plants of a variety of ploidy levels, including aneuploid, polyploid, diploid, haploid, and hemizygous.

A polynucleotide sequence is “heterologous” to an organism or a second polynucleotide sequence if it originates from a foreign species, or, if from the same species, is modified from its original form. For example, when a promoter is said to be operably linked to a heterologous coding sequence, it means that the coding sequence is derived from one species whereas the promoter sequence is derived another, different species; or, if both are derived from the same species, the coding sequence is not naturally associated with the promoter (e.g., is a genetically engineered coding sequence, e.g., from a different gene in the same species, or an allele from a different ecotype or variety).

A polynucleotide “exogenous” to an individual plant is a polynucleotide which is introduced into the plant by any means other than by a sexual cross. Examples of means by which this can be accomplished are described below, and include Agrobacterium-mediated transformation, biolistic methods, electroporation, and the like. Such a plant containing the exogenous nucleic acid is referred to here as a T₁ (e.g., in Arabidopsis by vacuum infiltration) or R₀ (for plants regenerated from transformed cells in vitro) generation transgenic plant.

As used herein, the term “transgenic” describes a non-naturally occurring plant that contains a genome modified by man, wherein the plant includes in its genome an exogenous nucleic acid molecule, which can be derived from the same or a different plant species. The exogenous nucleic acid molecule can be a gene regulatory element such as a promoter, enhancer, or other regulatory element, or can contain a coding sequence, which can be linked to a heterologous gene regulatory element. Transgenic plants that arise from sexual cross or by selfing are descendants of such a plant and are also considered “transgenic.”.

An “expression cassette” refers to a nucleic acid construct that, when introduced into a host cell, results in transcription and/or translation of an RNA or polypeptide, respectively. Antisense or sense constructs that are not or cannot be translated are expressly included by this definition. In the case of both expression of transgenes and suppression of endogenous genes (e.g., by antisense, or sense suppression) one of skill will recognize that the inserted polynucleotide sequence need not be identical, but may be only “substantially identical” to a sequence of the gene from which it was derived. As explained below, these substantially identical variants are specifically covered by reference to a specific nucleic acid sequence.

“Increased” or “enhanced” PYR/PYL expression or activity refers to an augmented change in the protein's expression or activity. Examples of such increased activity or expression include, e.g., where PYR/PYL expression is increased above control levels and/or where it is ectopically expressed, e.g., in a place or time where it is not expressed in a control. In some embodiments, PYR/PYL expression or activity is increased above the level of that in wild-type, non-transgenic control plants (i.e., the quantity of PYR/PYL activity or expression of the PYR/PYL gene is increased). In some embodiments, PYR/PYL expression or activity can be present, for example, in an organ, tissue, or cell where it is not normally detected in wild-type, non-transgenic control plants (i.e., PYR/PYL expression or activity is increased within certain tissue types). In some embodiments, PYR/PYL expression or activity is increased when its expression or activity is present in an organ, tissue or cell for a longer period than in a wild-type, non-transgenic controls (i.e., duration of PYR/PYL expression or activity is increased).

Two nucleic acid sequences or polypeptides are said to be “identical” if the sequence of nucleotides or amino acid residues, respectively, in the two sequences is the same when aligned for maximum correspondence as described below. The terms “identical” or percent “identity,” in the context of two or more nucleic acids or polypeptide sequences, refer to two or more sequences or subsequences that are the same or have a specified percentage of amino acid residues or nucleotides that are the same, when compared and aligned for maximum correspondence over a comparison window, as measured using one of the following sequence comparison algorithms or by manual alignment and visual inspection. When percentage of sequence identity is used in reference to proteins or peptides, it is recognized that residue positions that are not identical often differ by conservative amino acid substitutions, where amino acids residues are substituted for other amino acid residues with similar chemical properties (e.g., charge or hydrophobicity) and therefore do not change the functional properties of the molecule. Where sequences differ in conservative substitutions, the percent sequence identity may be adjusted upwards to correct for the conservative nature of the substitution. Means for making this adjustment are well known to those of skill in the art. Typically this involves scoring a conservative substitution as a partial rather than a full mismatch, thereby increasing the percentage sequence identity. Thus, for example, where an identical amino acid is given a score of 1 and a non-conservative substitution is given a score of zero, a conservative substitution is given a score between zero and 1. The scoring of conservative substitutions is calculated according to, e.g., the algorithm of Meyers & Miller, Computer Applic. Biol. Sci. 4:11-17 (1988) e.g., as implemented in the program PC/GENE (Intelligenetics, Mountain View, Calif., USA).

The phrase “substantially identical,” used in the context of two nucleic acids or polypeptides, refers to a sequence that has at least 25% sequence identity with a reference sequence. Alternatively, percent identity can be any integer from 25% to 100%. Some embodiments include at least: 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99%, compared to a reference sequence using the programs described herein; preferably BLAST using standard parameters, as described below. The present invention provides for nucleic acids encoding polypeptides that are substantially identical to any of SEQ ID NO:2-90 or 108-137.

For sequence comparison, typically one sequence acts as a reference sequence, to which test sequences are compared. When using a sequence comparison algorithm, test and reference sequences are entered into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. Default program parameters can be used, or alternative parameters can be designated. The sequence comparison algorithm then calculates the percent sequence identities for the test sequences relative to the reference sequence, based on the program parameters.

A “comparison window”, as used herein, includes reference to a segment of any one of the number of contiguous positions selected from the group consisting of from 20 to 600, usually about 50 to about 200, more usually about 100 to about 150 in which a sequence may be compared to a reference sequence of the same number of contiguous positions after the two sequences are optimally aligned. Methods of alignment of sequences for comparison are well-known in the art. Optimal alignment of sequences for comparison can be conducted, e.g., by the local homology algorithm of Smith & Waterman, Adv. Appl. Math. 2:482 (1981), by the homology alignment algorithm of Needleman & Wunsch, J. Mol. Biol. 48:443 (1970), by the search for similarity method of Pearson & Lipman, Proc. Nat'l. Acad. Sci. USA 85:2444 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, Wis.), or by manual alignment and visual inspection.

Examples of algorithms that are suitable for determining percent sequence identity and sequence similarity are the BLAST and BLAST 2.0 algorithms, which are described in Altschul et al. (1990) J. Mol. Biol. 215: 403-410 and Altschul et al. (1977) Nucleic Acids Res. 25: 3389-3402, respectively. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (NCBI) web site. The algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence, which either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighborhood word score threshold (Altschul et al, supra). These initial neighborhood word hits acts as seeds for initiating searches to find longer HSPs containing them. The word hits are then extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Cumulative scores are calculated using, for nucleotide sequences, the parameters M (reward score for a pair of matching residues; always >0) and N (penalty score for mismatching residues; always <0). For amino acid sequences, a scoring matrix is used to calculate the cumulative score. Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment. The BLASTN program (for nucleotide sequences) uses as defaults a word size (W) of 28, an expectation (E) of 10, M=1, N=−2, and a comparison of both strands. For amino acid sequences, the BLASTP program uses as defaults a word size (W) of 3, an expectation (E) of 10, and the BLOSUM62 scoring matrix (see Henikoff & Henikoff, Proc. Natl. Acad. Sci. USA 89:10915 (1989)).

The BLAST algorithm also performs a statistical analysis of the similarity between two sequences (see, e.g., Karlin & Altschul, Proc. Nat'l. Acad. Sci. USA 90:5873-5787 (1993)). One measure of similarity provided by the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance. For example, a nucleic acid is considered similar to a reference sequence if the smallest sum probability in a comparison of the test nucleic acid to the reference nucleic acid is less than about 0.01, more preferably less than about 10⁻⁵, and most preferably less than about 10⁻²⁰.

“Conservatively modified variants” applies to both amino acid and nucleic acid sequences. With respect to particular nucleic acid sequences, conservatively modified variants refers to those nucleic acids which encode identical or essentially identical amino acid sequences, or where the nucleic acid does not encode an amino acid sequence, to essentially identical sequences. Because of the degeneracy of the genetic code, a large number of functionally identical nucleic acids encode any given protein. For instance, the codons GCA, GCC, GCG and GCU all encode the amino acid alanine Thus, at every position where an alanine is specified by a codon, the codon can be altered to any of the corresponding codons described without altering the encoded polypeptide. Such nucleic acid variations are “silent variations,” which are one species of conservatively modified variations. Every nucleic acid sequence herein which encodes a polypeptide also describes every possible silent variation of the nucleic acid. One of skill will recognize that each codon in a nucleic acid (except AUG, which is ordinarily the only codon for methionine) can be modified to yield a functionally identical molecule. Accordingly, each silent variation of a nucleic acid which encodes a polypeptide is implicit in each described sequence.

As to amino acid sequences, one of skill will recognize that individual substitutions, in a nucleic acid, peptide, polypeptide, or protein sequence which alters a single amino acid or a small percentage of amino acids in the encoded sequence is a “conservatively modified variant” where the alteration results in the substitution of an amino acid with a chemically similar amino acid. Conservative substitution tables providing functionally similar amino acids are well known in the art.

The following six groups each contain amino acids that are conservative substitutions for one another:

1) Alanine (A), Serine (S), Threonine (T);

2) Aspartic acid (D), Glutamic acid (E);

3) Asparagine (N), Glutamine (Q);

4) Arginine (R), Lysine (K);

5) Isoleucine (I), Leucine (L), Methionine (M), Valine (V); and

6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W).

(see, e.g., Creighton, Proteins (1984)).

As used herein, the term “drought-resistance” or “drought-tolerance,” including any of their variations, refers to the ability of a plant to recover from periods of drought stress (i.e., little or no water for a period of days). Typically, the drought stress will be at least 5 days and can be as long as, for example, 18 to 20 days or more (e.g., at least 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 days), depending on, for example, the plant species.

DETAILED DESCRIPTION OF THE INVENTION

I. Introduction

The present invention is based, in part, on the discovery of selective abscisic acid (ABA) agonist small organic molecules as well as a protein, PYR1, which is required for the ABA agonist activity. It has further been discovered that PYR1 is a member of the PYR/PYL receptor protein family. Plants examined to date express more than one PYR/PYL receptor protein family members and have at least somewhat redundant activity. Increasing expression or activity of one or more PYR/PYL protein in a plant therefore will result in increased ABA sensitivity and accordingly improved stress (e.g. cold, heat, salinity, or drought) response and tolerance as well as other desirable ABA-mediated phenotypes.

Abscisic acid is a multifunctional phytohormone involved in a variety of phyto-protective functions including bud dormancy, seed dormancy and/or maturation, abscission of leaves and fruits, and response to a wide variety of biological stresses (e.g. cold, heat, salinity, and drought). ABA is also responsible for regulating stomatal closure by a mechanism independent of CO₂ concentration. Thus, because PYR/PYL ABA receptor proteins mediate ABA signalling, these phenotypes can be modulated by modulating expression of PYR/PYL. Phenotypes that are induced by ABA can be increased or speeded in plants with increased expression of PYR/PYL whereas such phenotypes can be reduced or slowed in plants with decreased expression of PYR/PYL. PYR/PYL mediates ABA signaling as a positive regulator in, for example, seed germination, post-germination growth, stomatal movement and plant tolerance to stress including, but not limited to, drought. Accordingly, when abscisic acid sensitivity is increased by overexpressing PYR/PYL, desirable characteristics in plants such as increased stress (e.g., drought) tolerance and delayed seed germination is achieved. Other desirable characteristics that can be generated in the plants of the invention include, e.g., a change in flowering time and/or increased chlorophyll content.

II. ABA Agonists

The present invention provides for small molecule ABA agonists, i.e., compounds that activate PYR/PYL proteins. Exemplary ABA agonists include, e.g., a compound selected from the following formulas:

-   -   wherein

R¹ is selected from the group consisting of aryl and heteroaryl, optionally substituted with 1-3 R^(1a) groups;

each R^(1a) is independently selected from the group consisting of H, halogen, C₁₋₆ alkyl, C₁₋₆ haloalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₁₋₆ alkoxy, C₁₋₆ haloalkoxy, C₁₋₆ hydroxyalkyl, —NR′R″, —SR′, —OH, —CN, —NO₂, —C(O)R′, —C(O)OR′, —C(O)NR′R″, —N(R′)C(O)R″, —N(R′)C(O)OR″, —N(R′)C(O)NR′R″, —OP(O)(OR′)₂, —S(O)₂OR′, —S(O)₂NR′R″, cycloalkyl, heterocycloalkyl, aryl and heteroaryl, wherein the aryl group is optionally substituted with —NO₂ and the heteroaryl group is optionally substituted with C₁₋₆ alkyl;

alternatively, adjacent R^(1a) groups can combine to form a member selected from the group consisting of cycloalkyl, heterocycloalkyl, aryl and heteroaryl, wherein the aryl group is optionally substituted with —OH;

R′ and R″ are each independently selected from the group consisting of H and C₁₋₆ alkyl;

R² is selected from the group consisting of C₂₋₆ alkenyl, cycloalkenyl, aryl and heteroaryl;

R³ is H or is optionally combined with R² and the atoms to which each is attached to form a heterocycloalkyl optionally substituted with 1-3 R^(1a) groups;

R⁴ is a heteroaryl, optionally substituted with 1-3 R^(1a) groups;

R⁵ is selected from the group consisting of C₁₋₆ alkyl and aryl, wherein the aryl is optionally substituted with 1-3 R^(1a) groups;

each of R⁶ and R⁷ are independently selected from the group consisting of aryl and heteroaryl, each optionally substituted with 1-3 R^(1a) groups;

R⁸ is selected from the group consisting of cycloalkyl and aryl, each optionally substituted with 1-3 R^(1a) groups;

R⁹ is H or is optionally combined with a R^(1a) group of R⁸ and the atoms to which each is attached to form a heterocycloalkyl; subscript n is 0-2;

X is absent or is selected from the group consisting of —O—, and —N(R′)—;

Y is absent or is selected from the group consisting of —C(O)— and —C(R′,R″)—;

Z is absent or is selected from the group consisting of —N═, and —C(S)—N(R′)—, such that one of Y and Z is absent;

each of R¹⁰ and R¹¹ are independently selected from the group consisting of H, C₁₋₆ alkyl, —C(O)OR′, and C₁₋₆ alkenyl-C(O)OH, wherein at least two of the R¹⁰ and R¹¹ groups are C₁₋₆ alkyl and at least one of the R¹⁰ and R¹¹ groups is C₁₋₆ alkenyl-C(O)OH;

alternatively, two R¹⁰ or R¹¹ groups attached to the same carbon are combined to form ═O;

alternatively, one R¹⁰ group and one R¹¹ group are combined to form a cycloalkyl having from 3 to 6 ring members;

each of subscripts k and m is an integer from 1 to 3, such that the sum of k and m is from 3 to 4;

each of subscripts p and r is an integer from 1 to 10;

wherein two of the R¹⁰ and R¹¹ groups on adjacent carbons are combined to form a bond;

R¹² is a C₁₋₆ alkyl, substituted with a ═O;

R¹³ is C₁₋₆ alkenyl-C(O)OH;

R¹⁴ is selected from the group consisting of H and C₁₋₆ alkyl; and

subscript r is an integer from 1 to 10;

with the proviso that when R¹ is 4-bromo-naphthalen-1-yl, and n is 1, R² is other than unsubstituted pyrid-2-yl

Exemplary compounds are further depicted in the Examples and Figures. See, e.g., FIGS. 9, 10, and 13.

The ABA agonist compounds of the present invention can be prepared by a variety of methods known to one of skill in the art. For example, the sulphonamide compounds can be prepared by reaction of a sulfonyl chloride and an amine to provide the sulphonamide. Amide compounds of the present invention can be prepared in a similar fashion using an acid chloride in place of the sulfonyl chloride, or carbodiimide coupling reagents known to one of skill in the art. Additional methods of making the compounds of the present invention are known to one of skill in the art, for example, those described in Comprehensive Organic Transformations, 2d ed., Richard C. Larock, 1999. The starting materials for the methods described above are commercially available (Sigma-Aldrich) or can be prepared by methods known to one of skill in the art.

Phenotypes that are induced by ABA can be increased or speeded in plants (or plant parts such as seeds) by contacting the plants with a sufficient amount of an ABA agonist of the invention to induce the ABA-inducible phenotypes. ABA agonists of the invention are useful as, e.g., positive enhancers of, for example, delayed seed germination, post-germination growth, stomatal movement and plant tolerance to stress including, but not limited to, drought.

III. ABA Agonist Formulations

The present invention provides for agricultural chemical formulation formulated for contacting to plants, wherein the formulation comprises an ABA agonist of the present invention. In some embodiments, the plants that are contacted with the agonists do not comprise or express a heterologous PYR/PYL polypeptide (e.g., the plants are not transgenic or are transgenic but express heterologous proteins other than heterologous PYR/PYL proteins). In some embodiments, the plants that are contacted with the agonists do comprise or express a heterologous PYR/PYL polypeptide as described herein.

The formulations can be suitable for treating plants or plant propagation material, such as seeds, in accordance with the present invention, e.g., in a carrier. Suitable additives include buffering agents, wetting agents, coating agents, polysaccharides, and abrading agents. Exemplary carriers include water, aqueous solutions, slurries, solids and dry powders (e.g., peat, wheat, bran, vermiculite, clay, pasteurized soil, many forms of calcium carbonate, dolomite, various grades of gypsum, bentonite and other clay minerals, rock phosphates and other phosphorous compounds, titanium dioxide, humus, talc, alginate and activated charcoal. Any agriculturally suitable carrier known to one skilled in the art would be acceptable and is contemplated for use in the present invention. Optionally, the formulations can also include at least one surfactant, herbicide, fungicide, pesticide, or fertilizer.

Treatment can be performed using a variety of known methods, e.g., by spraying, atomizing, dusting or scattering the compositions over the propagation material or brushing or pouring or otherwise contacting the compositions over the plant or, in the event of seed, by coating, encapsulating, or otherwise treating the seed. In an alternative to directly treating a plant or seed before planting, the formulations of the invention can also be introduced into the soil or other media into which the seed is to be planted. In some embodiments, a carrier is also used in this embodiment. The carrier can be solid or liquid, as noted above. In some embodiments peat is suspended in water as a carrier of the ABA agonist, and this mixture is sprayed into the soil or planting media and/or over the seed as it is planted.

IV. Screening for New ABA Agonists and Antagonists

The present invention also provides methods of screening for ABA agonists and antagonists by screening for a molecule's ability to induce PYR/PYL-PP2C binding in the case of agonists, or to disrupt the ability of ABA and other agonists to promote PYR/PYL-PP2C binding in the case of antagonists. A number of different screening protocols can be utilized to identify agents that agonize or antagonize a PYR/PYL polypeptide.

Screening can take place using isolated, purified or partially purified reagents. In some embodiments, purified or partially purified PYR/PYL polypeptide can be used.

Alternatively, cell-based methods of screening can be used. For example, cells that naturally-express a PYR/PYL polypeptide or that recombinantly express a PYR/PYL polypeptide can be used. In some embodiments, the cells used are plant cells, animal cells, bacterial cells, fungal cells, including but not limited to yeast cells, insect cells, or mammalian cells. In general terms, the screening methods involve screening a plurality of agents to identify an agent that modulates the activity of a PYR/PYL polypeptide by, e.g., binding to PYR/PYL polypeptide, or activating a PYR/PYL polypeptide or increasing expression of a PYR/PYL polypeptide, or a transcript encoding a PYR/PYL polypeptide.

1. PYR/PYL Polypeptide Binding Assays

Optionally, preliminary screens can be conducted by screening for agents capable of binding to a PYR/PRL polypeptide, as at least some of the agents so identified are likely PYR/PYL polypeptide modulators.

Binding assays can involve contacting a PYR/PYL polypeptide with one or more test agents and allowing sufficient time for the protein and test agents to form a binding complex. Any binding complexes formed can be detected using any of a number of established analytical techniques. Protein binding assays include, but are not limited to, methods that measure co-precipitation or co-migration on non-denaturing SDS-polyacrylamide gels, and co-migration on Western blots (see, e.g., Bennet, J. P. and Yamamura, H. I. (1985) “Neurotransmitter, Hormone or Drug Receptor Binding Methods,” in Neurotransmitter Receptor Binding (Yamamura, H. I., et al., eds.), pp. 61-89. Other binding assays involve the use of mass spectrometry or NMR techniques to identify molecules bound to PYR/PYL polypeptide or displacement of labeled substrates (e.g., labeled ABA). The PYR/PYL polypeptide protein utilized in such assays can be naturally expressed, cloned or synthesized.

2. Activity

PYR/PYL polypeptide agonists can be identified by screening for agents that activate or increase activity of a PYR/PYL polypeptide. Antagonists can be identified by reducing activity.

One activity assay involves testing whether a candidate agonist can induce binding of a PYR/PYL protein to a type 2 protein phosphatase (PP2C) polypeptide in an agonist-specific fashion. Mammalian or yeast two-hybrid approaches (see, e.g., artel, P. L. et. al. Methods Enzymol, 254:241 (1995)) can be used to identify polypeptides or other molecules that interact or bind when expressed together in a cell. In some embodiments, agents that agonize a PYR/PYL polypeptide are identified in a two-hybrid assay between a PYR/PYL polypeptide and a type 2 protein phosphatase (PP2C) polypeptide, wherein an ABA agonist is identified as an agent that activates or enables binding of the PYR/PYL polypeptide and the PP2C polypeptide. Thus, the two polypeptides bind in the presence, but not in the absence of the agent.

In some embodiments, agents that antagonize a PYR/PYL polypeptide are identified in a two-hybrid assay between a PYR/PYL polypeptide and a type 2 protein phosphatase (PP2C) polypeptide, wherein an ABA antagonist is identified as an agent that decreases binding of the PYR/PYL polypeptide and the PP2C polypeptide, optionally in the presence of ABA or a PYR/PYL ABA agonist. Thus, the antagonist blocks the normal binding of the two polypeptides that is normally promoted by ABA or other agonists, or alternatively, that is observed in constitutively interacting PYR/PYL proteins.

3. Expression Assays

Screening for a compound that increases the expression of a PYR/PYL polypeptide is also provided. Screening methods generally involve conducting cell-based or plant-based assays in which test compounds are contacted with one or more cells expressing PYR/PYL polypeptide, and then detecting an increase in PYR/PYL expression (either transcript or translation product). Assays can be performed with cells that naturally express PYR/PYL or in cells recombinantly altered to express PYR/PYL, or in cells recombinantly altered to express a reporter gene under the control of the PYR/PYL promoter.

Various controls can be conducted to ensure that an observed activity is authentic including running parallel reactions with cells that lack the reporter construct or by not contacting a cell harboring the reporter construct with test compound.

4. Validation

Agents that are initially identified by any of the foregoing screening methods can be further tested to validate the apparent activity and/or determine other biological effects of the agent. In some cases, the identified agent is tested for the ability to effect plant stress (e.g., drought tolerance), seed germination, or another phenotype affected by ABA. A number of such assays and phenotypes are known in the art and can be employed according to the methods of the invention.

5. Solid Phase and Soluble High Throughput Assays

In the high throughput assays of the invention, it is possible to screen up to several thousand different modulators or ligands in a single day. In particular, each well of a microtiter plate can be used to run a separate assay against a selected potential modulator, or, if concentration or incubation time effects are to be observed, every 5-10 wells can test a single modulator. Thus, a single standard microtiter plate can assay about 100 (e.g., 96) modulators. If 1536 well plates are used, then a single plate can easily assay from about 100 to about 1500 different compounds. It is possible to assay several different plates per day; assay screens for up to about 6,000-20,000 or more different compounds are possible using the integrated systems of the invention. In addition, microfluidic approaches to reagent manipulation can be used.

The molecule of interest (e.g., PYR/PYL or a cell expressing a PYR/PYL polypeptide) can be bound to the solid state component, directly or indirectly, via covalent or non covalent linkage.

The invention provides in vitro assays for identifying, in a high throughput format, compounds that can modulate the expression or activity of PYR/PYL.

V. PYR/PYL Receptor Polypeptides

Polypeptides of the invention, when expressed in plants, mediate ABA and ABA analog signaling. In some embodiments, the PYR/PYL polypeptides interact (e.g., in a yeast two-hybrid assay) with a PP2C polypeptide (e.g., ABI1 or 2 or orthologs thereof, e.g., from the group A subfamily of PP2Cs) in an ABA, pyrabactin, or other ABA agonist—dependent manner as described herein.

A wide variety of PYR/PYL polypeptide sequences are known in the art and can be used according to the methods and compositions of the invention. As noted herein, while PYR1 was originally identified as an ABA receptor in Arabidopsis, in fact PYR1 is a member of a group of at least 14 proteins (PYR/PYL proteins) in the same protein family in Arabidopsis and that also mediate ABA signaling. This protein family is also present in other plants (see, e.g., SEQUENCE LISTING) is characterized in part by the presence of one or more or all of a polyketide cyclase domain 2 (PF10604), a polyketide cyclase domain 1 (PF03364), and a Bet V I domain (PF03364). START/Bet v 1 superfamily domain are described in, for example, Radauer, BMC Evol. Biol. 8:286 (2008).

In situations where variants or orthologs of the above sequences are desired, it can be useful to generate sequence alignments to identify conserved amino acid or motifs (i.e., where alteration in sequences may alter protein function) and regions where variation occurs in alignment of sequences (i.e., where variation of sequence is not likely to significantly affect protein activity). SEQ ID NO:1, 91, and 92 provide consensus sequences useful for identifying PYR/PYL polypeptides. Other useful consensus sequences include, e.g., EXLXXXDXXXXXXXXXXXGGXHXL (SEQ ID NO:138); CxSxxxxxxxAPxxxxWxxxxxFxxPxxxxxFxxxC (SEQ ID NO:93), GxxRxVxxxSxxPAxxSxExLxxxD (SEQ ID NO:94), and/or GGxHRLxNYxS (SEQ ID NO:95). In addition, more specific consensus sequences can be represented by aligning subsets of the 14 members of the Arabidopsis PYR/PYL proteins. Examples of such consensus sequences include, e.g.,

PYR1 to PYL12 (SEQ ID NO: 96) CxSxxxxxxxAPxxxxWxxxxxFxxPxxxKxFxxxC (SEQ ID NO: 97) GxxRxVxxxSxLPAxxSxExLxxxD (SEQ ID NO: 98) GGxHRLxNYxS (SEQ ID NO: 99) ESxxVDxPxGNxxxxTxxFxxxxxxxNLxxL PYR1-PYL6 (SEQ ID NO: 100) HxxxxxxxxCxSxxxxxxxAPxxxxWxxxxxFxxPxxYKxFxxxC (SEQ ID NO: 101) VGRxVxVxSGLPAxxSxExLxxxDxxxxxxxFxxxGGxHRLxNYxSVT (SEQ ID NO: 102) VxESYxVDxPxGNxxxxTxxFxDxxxxxNLQxL PYL7-PYL10 (SEQ ID NO: 103) HxHxxxxxQCxSxLVKxIxAPxHxVWSxVRRFDxPQKYKPFxSRCxVxGx (SEQ ID NO: 104) ExGxxREVxxKSGLPATxSTExLExLDDxEHILxIxIxGGDHRLKNYSSxxxxHxExIxGxxGTx (SEQ ID NO: 105) xxESFVVDVPxGNTKxxTCxFVExLIxCNLxSLAxxxERL PYL11-PYL13 (SEQ ID NO: 106) CxSxxVxTIxAPLxLVWSILRxFDxPxxxxxFVKxCxxxSGxGG (SEQ ID NO: 107) GSVRxVTxVSxxPAxFSxERLxELDDESHVMxxSIIGGxHRLVNYxSKT Accordingly, in some embodiments, the PYR/PYL polypeptides of the invention comprise one or more of the above-described consensus sequences or conservative variants thereof.

Those of skill in the art will recognize that the variable positions within the above consensus sequences can be selected based on what amino acids occur at their corresponding positions in specific PYR1 polypeptides (e.g., as occur in any of SEQ ID NOs:2-90) or alternatively can be conservative substitutions thereof. In some embodiments, the PYR/PYL polypeptides of the invention are substantially identical to (e.g., at least 70%, 75%, 80%, 85%, 90%, 95% identical to) any of SEQ ID NO:2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, or 137.

The present invention provides for use of the above proteins and/or nucleic acid sequences, encoding such polypeptides, in the methods and compositions (e.g., expression cassettes, plants, etc.) of the present invention. The isolation of a polynucleotide sequence encoding a plant PYR/PYL (e.g., from plants where PYR/PYL sequences have not yet been identified) may be accomplished by a number of techniques. For instance, oligonucleotide probes based on the PYR/PYL coding sequences disclosed (e.g., as listed in the SEQUENCE LISTING) here can be used to identify the desired PYR/PYL gene in a cDNA or genomic DNA library. To construct genomic libraries, large segments of genomic DNA are generated by random fragmentation, e.g., using restriction endonucleases, and are ligated with vector DNA to form concatemers that can be packaged into the appropriate vector. To prepare a cDNA library, mRNA is isolated from the desired tissue, such as a leaf from a particular plant species, and a cDNA library containing the gene transcript of interest is prepared from the mRNA. Alternatively, cDNA may be prepared from mRNA extracted from other tissues in which PYR/PYL gene is expressed.

The cDNA or genomic library can then be screened using a probe based upon the sequence of a PYR/PYL gene disclosed here. Probes may be used to hybridize with genomic DNA or cDNA sequences to isolate homologous genes in the same or different plant species. Alternatively, antibodies raised against a polypeptide can be used to screen an mRNA expression library.

Alternatively, the nucleic acids encoding PYR/PYL can be amplified from nucleic acid samples using amplification techniques. For instance, polymerase chain reaction (PCR) technology can be used to amplify the coding sequences of PYR/PYL directly from genomic DNA, from cDNA, from genomic libraries or cDNA libraries. PCR and other in vitro amplification methods may also be useful, for example, to clone polynucleotide sequences encoding PYR/PYL to be expressed, to make nucleic acids to use as probes for detecting the presence of the desired mRNA in samples, for nucleic acid sequencing, or for other purposes. For a general overview of PCR see PCR Protocols: A Guide to Methods and Applications. (Innis, M, Gelfand, D., Sninsky, J. and White, T., eds.), Academic Press, San Diego (1990). Appropriate primers and probes for identifying sequences from plant tissues are generated from comparisons of the sequences provided here with other related genes.

In some embodiments, the partial or entire genome of a number of plants has been sequenced and open reading frames identified. By a BLAST search, one can identify the coding sequence for PYR/PYL in various plants.

Variants from naturally-occurring PYR/PYL polypeptides (or nucleic acids encoding such polypeptides) are contemplated by the term PYR/PYL polypeptide. Variants include, e.g., fusion proteins, deletions or mutations that retain activity.

In some embodiments, the PYR/PYL polypeptide is activated (e.g., as measured in a two-hybrid assay with PP2C or other receptor assays) in the presence of ABA (or ABA agonist) but is not significantly active in the absence of ABA or agonist. Alternatively, in some embodiments, the PYR/PYL polypeptides of the invention are constitutively active, i.e., are active in the absence of ABA or an ABA agonist. As described in the Examples, the inventors have found that the mutations H60P, M158T, M158I, M158S, or M158V in Arabidopsis PYR1 changes the protein to a constitutively active protein. As both of these positions (H60 and M158) are present on the dimer interface of the PYR/PYL protein, it is believed that other constitutive mutants can be generated by introducing amino acid changes at other dimer interface positions (e.g., F61, K63, I84, S85, L87, P88, A89, S152, D155, T156, F159, T162, L166, and/or K170). While the positions above are made with reference to the Arabidopsis PYR1 protein, it is intended that the corresponding position in other PYR/PYL polypeptides are also included in the above description. The corresponding position in another PYR/PYL polypeptide can be readily determined using standard alignment software such as BLAST. While specific amino acid changes are described above, the invention is intended to encompass mutations to other amino acids aside those specifically described above. In some embodiments, for example, conservative amino acids can be included in place of the mutations set forth above.

Interestingly, the inventors have observed that some naturally occurring PYR/PYL proteins naturally have a P at the position that corresponds to H60. For example, Arabidopsis PYL9 has a P at this position. The inventors have found that PYL9 is constitutively active. In some embodiments, a constitutively active PYR/PYL protein is converted to a protein activated by ABA or an ABA agonist by changing a proline at position “H60” (with reference to the position in Arabidopsis PYR1) to a Histidine or other non-proline amino acid.

Accordingly, the present invention provides for PYR/PYL polypeptides that are constitutively active and having a mutation as described above. In some embodiments, the constitutive polypeptides will comprise one or more of the above-described consensus sequences and/or will be substantially identical to one of SEQ ID NOs:2-90.

VI. Use of PYR/PYL Nucleic Acids and Polypeptides of the Invention

The invention provides methods of modulating ABA sensitivity in a plant by altering PYR/PYL expression or activity, for example, by introducing into a plant a recombinant expression cassette comprising a regulatory element (e.g., a promoter) operably linked to a PYR/PYL polynucleotide, i.e., a nucleic acid encoding PYR/PYL or a sequence comprising a portion of the sequence of a PYR/PYL mRNA or complement thereof.

In some embodiments, the methods of the invention comprise increasing and/or ectopically expressing one or more PYR/PYL polynucleotide encoding a PYR/PYL polypeptide in a plant. Such embodiments are useful for increasing ABA sensitivity of a plant, and resulting in, for example, improved stress (e.g., drought) tolerance and/or delayed seed germination (to avoid pre-mature germination, for example as can occur in humid environments or due to other exposure to moisture). For stress tolerance, promoters can be selected that are generally constitutive and are expressed in most plant tissues, or can be leaf or root specific. To affect seed germination, promoters are generally used that result in expression in seed or, in some embodiments, floral organs or embryos.

In some embodiments, the methods of the invention comprise decreasing endogenous PYR/PYL expression in plant, thereby decreasing ABA sensitivity in the plant. Such methods can involve, for example, mutagenesis (e.g., chemical, radiation, transposon or other mutagenesis) of PYR/PYL sequences in a plant to reduce PYR/PYL expression or activity, or introduction of a polynucleotide substantially identical to at least a portion of a PYR/PYL cDNA sequence or a complement thereof (e.g., an “RNAi construct”) to reduce PYR/PYL expression. Decreased (or increased) PYR/PYL expression can be used to control the development of abscission zones in leaf petioles and thereby control leaf loss, i.e., delay leaf loss if expression is decreased and speed leaf loss if expression is increased in abscission zones in a leaf.

A. Increasing PYR/PYL Expression or Activity

Isolated sequences prepared as described herein can also be used to prepare expression cassettes that enhance or increase PYR/PYL gene expression. Where overexpression of a gene is desired, the desired gene (or at least the polynucleotide encoding a PYR/PYL polypeptide) from the same species or a different species (or substantially identical to the gene or polynucleotide encoding a PYR/PYL polypeptide from another species) may be used. In some embodiments, to decrease potential sense suppression effects, a polynucleotide encoding a PYR/PYL polypeptide from a different species (or substantially identical to the gene or polynucleotide encoding a PYR/PYL polypeptide from another species) may be used.

Any of a number of means well known in the art can be used to increase PYR/PYL activity in plants. Any organ or plant part can be targeted, such as shoot vegetative organs/structures (e.g. leaves, stems and tubers), roots, flowers and floral organs/structures (e.g. bracts, sepals, petals, stamens, carpels, anthers and ovules), seed (including embryo, endosperm, and seed coat), fruit, abscission zone, etc. Alternatively, one or several PYR/PYL genes can be expressed constitutively (e.g., using the CaMV 35S promoter or other constitutive promoter).

One of skill will recognize that the polypeptides encoded by the genes of the invention, like other proteins, have different domains which perform different functions. Thus, the overexpressed or ectopically expressed polynucleotide sequences need not be full length, so long as the desired functional domain of the protein is expressed. Alternatively, or in addition, active PYR/PYL proteins can be expressed as fusions, without necessarily significantly altering PYR/PYL activity. Examples of fusion partners include, but are not limited to, poly-His or other tag sequences.

B. Decreasing PYR/PYL Expression or Activity

A number of methods can be used to inhibit gene expression in plants. A variety of methods to inhibit gene expression are known and can be used to inhibit expression of one of more PYR/PYL genes. See, e.g., U.S. Pat. Nos. 5,759,829; 5,107,065; 5,231,020; 5,283,184; 6,506,559; 6,573,099, 6,326,193; 7,109,393. For instance, antisense technology can be conveniently used. To accomplish this, a nucleic acid segment from the desired gene is cloned and operably linked to a promoter such that the antisense strand of RNA will be transcribed. The expression cassette is then transformed into plants and the antisense strand of RNA is produced. In plant cells, it has been suggested that antisense RNA inhibits gene expression by preventing the accumulation of mRNA which encodes the enzyme of interest, see, e.g., Sheehy et al., Proc. Nat. Acad. Sci. USA, 85:8805-8809 (1988); Pnueli et al., The Plant Cell 6:175-186 (1994); and Hiatt et al., U.S. Pat. No. 4,801,340.

The antisense nucleic acid sequence transformed into plants will be substantially identical to at least a portion of the endogenous gene or genes to be repressed. The sequence, however, does not have to be perfectly identical to inhibit expression. Thus, an antisense or sense nucleic acid molecule encoding only a portion of PYR/PYL polypeptide, or a portion of the PYR/PYL cDNA, can be useful for producing a plant in which PYR/PYL expression is suppressed. The vectors of the present invention can be designed such that the inhibitory effect applies to other proteins within a family of genes exhibiting homology or substantial homology to the target gene. In some embodiments, it may be desirable to inhibit the expression of more than one PYR/PYL polypeptide at the same time using one or more antisense or sense or other siRNA nucleic acid molecules.

For antisense suppression, the introduced sequence also need not be full length relative to either the primary transcription product or fully processed mRNA. Generally, higher homology can be used to compensate for the use of a shorter sequence. Furthermore, the introduced sequence need not have the same intron or exon pattern, and homology of non-coding segments may be equally effective. For example, a sequence of between about 30 or 40 nucleotides can be used, and in some embodiments, about full length nucleotides should be used, though a sequence of at least about 20, 50 100, 200, or 500 nucleotides can be used.

Catalytic RNA molecules or ribozymes can also be used to inhibit expression of PYR/PYL genes. It is possible to design ribozymes that specifically pair with virtually any target RNA and cleave the phosphodiester backbone at a specific location, thereby functionally inactivating the target RNA. In carrying out this cleavage, the ribozyme is not itself altered, and is thus capable of recycling and cleaving other molecules, making it a true enzyme. The inclusion of ribozyme sequences within antisense RNAs confers RNA-cleaving activity upon them, thereby increasing the activity of the constructs.

A number of classes of ribozymes have been identified. One class of ribozymes is derived from a number of small circular RNAs that are capable of self-cleavage and replication in plants. The RNAs replicate either alone (viroid RNAs) or with a helper virus (satellite RNAs). Examples include RNAs from avocado sunblotch viroid and the satellite RNAs from tobacco ringspot virus, lucerne transient streak virus, velvet tobacco mottle virus, solanum nodiflorum mottle virus and subterranean clover mottle virus. The design and use of target RNA-specific ribozymes is described in Haseloff et al. Nature, 334:585-591 (1988).

Another method of suppression is sense suppression (also known as co-suppression). Introduction of expression cassettes in which a nucleic acid is configured in the sense orientation with respect to the promoter has been shown to be an effective means by which to block the transcription of target genes. For an example of the use of this method to modulate expression of endogenous genes see, Napoli et al., The Plant Cell 2:279-289 (1990); Flavell, Proc. Natl. Acad. Sci., USA 91:3490-3496 (1994); Kooter and Mol, Current Opin. Biol. 4:166-171 (1993); and U.S. Pat. Nos. 5,034,323, 5,231,020, and 5,283,184.

Generally, where inhibition of expression is desired, some transcription of the introduced sequence occurs. The effect may occur where the introduced sequence contains no coding sequence per se, but only intron or untranslated sequences homologous to sequences present in the primary transcript of the endogenous sequence. The introduced sequence generally will be substantially identical to the endogenous sequence intended to be repressed. This minimal identity will typically be greater than about 65%, but a higher identity can exert a more effective repression of expression of the endogenous sequences. In some embodiments, sequences with substantially greater identity are used, e.g., at least about 80, at least about 95%, or 100% identity are used. As with antisense regulation, the effect can be designed and tested to apply to any other proteins within a similar family of genes exhibiting homology or substantial homology.

For sense suppression, the introduced sequence in the expression cassette, needing less than absolute identity, also need not be full length, relative to either the primary transcription product or fully processed mRNA. This may be preferred to avoid concurrent production of some plants that are overexpressers. A higher identity in a shorter than full length sequence compensates for a longer, less identical sequence. Furthermore, the introduced sequence need not have the same intron or exon pattern, and identity of non-coding segments will be equally effective. In some embodiments, a sequence of the size ranges noted above for antisense regulation is used, i.e., 30-40, or at least about 20, 50, 100, 200, 500 or more nucleotides.

Endogenous gene expression may also be suppressed by means of RNA interference (RNAi) (and indeed co-suppression can be considered a type of RNAi), which uses a double-stranded RNA having a sequence identical or similar to the sequence of the target gene. RNAi is the phenomenon in which when a double-stranded RNA having a sequence identical or similar to that of the target gene is introduced into a cell, the expressions of both the inserted exogenous gene and target endogenous gene are suppressed. The double-stranded RNA may be formed from two separate complementary RNAs or may be a single RNA with internally complementary sequences that form a double-stranded RNA. Although complete details of the mechanism of RNAi are still unknown, it is considered that the introduced double-stranded RNA is initially cleaved into small fragments, which then serve as indexes of the target gene in some manner, thereby degrading the target gene. RNAi is known to be also effective in plants (see, e.g., Chuang, C. F. & Meyerowitz, E. M., Proc. Natl. Acad. Sci. USA 97: 4985 (2000); Waterhouse et al., Proc. Natl. Acad. Sci. USA 95:13959-13964 (1998); Tabara et al. Science 282:430-431 (1998); Matthew, Comp Funct Genom 5: 240-244 (2004); Lu, et al., Nucleic Acids Research 32(21):e171 (2004)). For example, to achieve suppression of the expression of a DNA encoding a protein using RNAi, a double-stranded RNA having the sequence of a DNA encoding the protein, or a substantially similar sequence thereof (including those engineered not to translate the protein) or fragment thereof, is introduced into a plant of interest. The resulting plants may then be screened for a phenotype associated with the target protein and/or by monitoring steady-state RNA levels for transcripts encoding the protein. Although the genes used for RNAi need not be completely identical to the target gene, they may be at least 70%, 80%, 90%, 95% or more identical to the target (e.g., PYR/PYL) gene sequence. See, e.g., U.S. Patent Publication No. 2004/0029283. The constructs encoding an RNA molecule with a stem-loop structure that is unrelated to the target gene and that is positioned distally to a sequence specific for the gene of interest may also be used to inhibit target gene expression. See, e.g., U.S. Patent Publication No. 2003/0221211.

The RNAi polynucleotides can encompass the full-length target RNA or may correspond to a fragment of the target RNA. In some cases, the fragment will have fewer than 100, 200, 300, 400, 500 600, 700, 800, 900 or 1,000 nucleotides corresponding to the target sequence. In addition, in some embodiments, these fragments are at least, e.g., 50, 100, 150, 200, or more nucleotides in length. In some cases, fragments for use in RNAi will be at least substantially similar to regions of a target protein that do not occur in other proteins in the organism or may be selected to have as little similarity to other organism transcripts as possible, e.g., selected by comparison to sequences in analyzing publicly-available sequence databases.

Expression vectors that continually express siRNA in transiently- and stably-transfected have been engineered to express small hairpin RNAs, which get processed in vivo into siRNAs molecules capable of carrying out gene-specific silencing (Brummelkamp et al., Science 296:550-553 (2002), and Paddison, et al., Genes & Dev. 16:948-958 (2002)). Post-transcriptional gene silencing by double-stranded RNA is discussed in further detail by Hammond et al. Nature Rev Gen 2: 110-119 (2001), Fire et al. Nature 391: 806-811 (1998) and Timmons and Fire Nature 395: 854 (1998).

One of skill in the art will recognize that using technology based on specific nucleotide sequences (e.g., antisense or sense suppression technology), families of homologous genes can be suppressed with a single sense or antisense transcript. For instance, if a sense or antisense transcript is designed to have a sequence that is conserved among a family of genes, then multiple members of a gene family can be suppressed. Conversely, if the goal is to only suppress one member of a homologous gene family, then the sense or antisense transcript should be targeted to sequences with the most variance between family members.

Another means of inhibiting PYR/PYL function in a plant is by creation of dominant negative mutations. In this approach, non-functional, mutant PYR/PYL polypeptides, which retain the ability to interact with wild-type subunits are introduced into a plant. A dominant negative construct also can be used to suppress PYR/PYL expression in a plant. A dominant negative construct useful in the invention generally contains a portion of the complete PYR/PYL coding sequence sufficient, for example, for DNA-binding or for a protein-protein interaction such as a homodimeric or heterodimeric protein-protein interaction but lacking the transcriptional activity of the wild type protein.

VII. Recombinant Expression Vectors

Once the coding or cDNA sequence for PYR/PYL is obtained, it can also be used to prepare an expression cassette for expressing the PYR/PYL protein in a transgenic plant, directed by a heterologous promoter. Increased expression of PYR/PYL polynucleotide is useful, for example, to produce plants with enhanced drought-resistance. Alternatively, as described above, expression vectors can also be used to express PYR/PYL polynucleotides and variants thereof that inhibit endogenous PYR/PYL expression.

Any of a number of means well known in the art can be used to increase or decrease PYR/PYL activity or expression in plants. Any organ can be targeted, such as shoot vegetative organs/structures (e.g. leaves, stems and tubers), roots, flowers and floral organs/structures (e.g. bracts, sepals, petals, stamens, carpels, anthers and ovules), seed (including embryo, endosperm, and seed coat) and fruit. Alternatively, the PYR/PYL gene can be expressed constitutively (e.g., using the CaMV 35S promoter).

To use PYR/PYL coding or cDNA sequences in the above techniques, recombinant DNA vectors suitable for transformation of plant cells are prepared. Techniques for transforming a wide variety of higher plant species are well known and described in the technical and scientific literature. See, e.g., Weising et al. Ann. Rev. Genet. 22:421-477 (1988). A DNA sequence coding for the PYR/PYL polypeptide preferably will be combined with transcriptional and translational initiation regulatory sequences which will direct the transcription of the sequence from the gene in the intended tissues of the transformed plant.

For example, a plant promoter fragment may be employed to direct expression of the PYR/PYL gene in all tissues of a regenerated plant. Such promoters are referred to herein as “constitutive” promoters and are active under most environmental conditions and states of development or cell differentiation. Examples of constitutive promoters include the cauliflower mosaic virus (CaMV) 35S transcription initiation region, the 1′- or 2′-promoter derived from T-DNA of Agrobacterium tumafaciens, and other transcription initiation regions from various plant genes known to those of skill.

Alternatively, the plant promoter may direct expression of the PYR/PYL protein in a specific tissue (tissue-specific promoters) or may be otherwise under more precise environmental control (inducible promoters). Examples of tissue-specific promoters under developmental control include promoters that initiate transcription only in certain tissues, such as leaves or guard cells (including but not limited to those described in WO/2005/085449; U.S. Pat. No. 6,653,535; Li et al., Sci China C Life Sci. 2005 April; 48(2):181-6; Husebye, et al., Plant Physiol, April 2002, Vol. 128, pp. 1180-1188; and Plesch, et al., Gene, Volume 249, Number 1, 16 May 2000, pp. 83-89(7)). Examples of environmental conditions that may affect transcription by inducible promoters include anaerobic conditions, elevated temperature, or the presence of light.

If proper protein expression is desired, a polyadenylation region at the 3′-end of the coding region should be included. The polyadenylation region can be derived from the natural gene, from a variety of other plant genes, or from T-DNA.

The vector comprising the sequences (e.g., promoters or PYR/PYL coding regions) will typically comprise a marker gene that confers a selectable phenotype on plant cells. For example, the marker may encode biocide resistance, particularly antibiotic resistance, such as resistance to kanamycin, G418, bleomycin, hygromycin, or herbicide resistance, such as resistance to chlorosluforon or Basta.

In some embodiments, the PYR/PYL nucleic acid sequence is expressed recombinantly in plant cells to enhance and increase levels of total PYR/PYL polypeptide. A variety of different expression constructs, such as expression cassettes and vectors suitable for transformation of plant cells can be prepared. Techniques for transforming a wide variety of higher plant species are well known and described in the technical and scientific literature. See, e.g., Weising et al. Ann. Rev. Genet. 22:421-477 (1988). A DNA sequence coding for a PYR/PYL protein can be combined with cis-acting (promoter) and trans-acting (enhancer) transcriptional regulatory sequences to direct the timing, tissue type and levels of transcription in the intended tissues of the transformed plant. Translational control elements can also be used.

The invention provides a PYR/PYL nucleic acid operably linked to a promoter which, in some embodiments, is capable of driving the transcription of the PYR/PYL coding sequence in plants. The promoter can be, e.g., derived from plant or viral sources. The promoter can be, e.g., constitutively active, inducible, or tissue specific. In construction of recombinant expression cassettes, vectors, transgenics, of the invention, a different promoters can be chosen and employed to differentially direct gene expression, e.g., in some or all tissues of a plant or animal.

A. Constitutive Promoters

A promoter fragment can be employed to direct expression of a PYR/PYL nucleic acid in all transformed cells or tissues, e.g., as those of a regenerated plant. The term “constitutive regulatory element” means a regulatory element that confers a level of expression upon an operatively linked nucleic molecule that is relatively independent of the cell or tissue type in which the constitutive regulatory element is expressed. A constitutive regulatory element that is expressed in a plant generally is widely expressed in a large number of cell and tissue types. Promoters that drive expression continuously under physiological conditions are referred to as “constitutive” promoters and are active under most environmental conditions and states of development or cell differentiation.

A variety of constitutive regulatory elements useful for ectopic expression in a transgenic plant are well known in the art. The cauliflower mosaic virus 35S (CaMV 35S) promoter, for example, is a well-characterized constitutive regulatory element that produces a high level of expression in all plant tissues (Odell et al., Nature 313:810-812 (1985)). The CaMV 35S promoter can be particularly useful due to its activity in numerous diverse plant species (Benfey and Chua, Science 250:959-966 (1990); Futterer et al., Physiol. Plant 79:154 (1990); Odell et al., supra, 1985). A tandem 35S promoter, in which the intrinsic promoter element has been duplicated, confers higher expression levels in comparison to the unmodified 35S promoter (Kay et al., Science 236:1299 (1987)). Other useful constitutive regulatory elements include, for example, the cauliflower mosaic virus 19S promoter; the Figwort mosaic virus promoter; and the nopaline synthase (nos) gene promoter (Singer et al., Plant Mol. Biol. 14:433 (1990); An, Plant Physiol. 81:86 (1986)).

Additional constitutive regulatory elements including those for efficient expression in monocots also are known in the art, for example, the pEmu promoter and promoters based on the rice Actin-1 5′ region (Last et al., Theor. Appl. Genet. 81:581 (1991); Mcelroy et al., Mol. Gen. Genet. 231:150 (1991); Mcelroy et al., Plant Cell 2:163 (1990)). Chimeric regulatory elements, which combine elements from different genes, also can be useful for ectopically expressing a nucleic acid molecule encoding a PYR/PYL protein (Comai et al., Plant Mol. Biol. 15:373 (1990)).

Other examples of constitutive promoters include the 1′- or 2′-promoter derived from T-DNA of Agrobacterium tumafaciens (see, e.g., Mengiste (1997) supra; O'Grady (1995) Plant Mol. Biol. 29:99-108); actin promoters, such as the Arabidopsis actin gene promoter (see, e.g., Huang (1997) Plant Mol. Biol. 1997 33:125-139); alcohol dehydrogenase (Adh) gene promoters (see, e.g., Millar (1996) Plant Mol. Biol. 31:897-904); ACT11 from Arabidopsis (Huang et al. Plant Mol. Biol. 33:125-139 (1996)), Cat3 from Arabidopsis (GenBank No. U43147, Zhong et al., Mol. Gen. Genet. 251:196-203 (1996)), the gene encoding stearoyl-acyl carrier protein desaturase from Brassica napus (Genbank No. X74782, Solocombe et al. Plant Physiol. 104:1167-1176 (1994)), GPc1 from maize (GenBank No. X15596, Martinez et al. J. Mol. Biol 208:551-565 (1989)), Gpc2 from maize (GenBank No. U45855, Manjunath et al., Plant Mol. Biol. 33:97-112 (1997)), other transcription initiation regions from various plant genes known to those of skill. See also Holtorf Plant Mol. Biol. 29:637-646 (1995).

B. Inducible Promoters

Alternatively, a plant promoter may direct expression of the PYR/PYL gene under the influence of changing environmental conditions or developmental conditions. Examples of environmental conditions that may effect transcription by inducible promoters include anaerobic conditions, elevated temperature, drought, or the presence of light. Such promoters are referred to herein as “inducible” promoters. For example, the invention can incorporate drought-specific promoter such as the drought-inducible promoter of maize (Busk (1997) supra); or alternatively the cold, drought, and high salt inducible promoter from potato (Kirch (1997) Plant Mol. Biol. 33:897-909).

Alternatively, plant promoters which are inducible upon exposure to plant hormones, such as auxins, are used to express the PYR/PYL gene. For example, the invention can use the auxin-response elements E1 promoter fragment (AuxREs) in the soybean (Glycine max L.) (Liu (1997) Plant Physiol. 115:397-407); the auxin-responsive Arabidopsis GST6 promoter (also responsive to salicylic acid and hydrogen peroxide) (Chen (1996) Plant J. 10: 955-966); the auxin-inducible parC promoter from tobacco (Sakai (1996) 37:906-913); a plant biotin response element (Streit (1997) Mol. Plant Microbe Interact. 10:933-937); and, the promoter responsive to the stress hormone abscisic acid (Sheen (1996) Science 274:1900-1902).

Plant promoters inducible upon exposure to chemicals reagents that may be applied to the plant, such as herbicides or antibiotics, are also useful for expressing the PYR/PYL gene. For example, the maize In2-2 promoter, activated by benzenesulfonamide herbicide safeners, can be used (De Veylder (1997) Plant Cell Physiol. 38:568-577); application of different herbicide safeners induces distinct gene expression patterns, including expression in the root, hydathodes, and the shoot apical meristem. A PYR/PYL coding sequence can also be under the control of, e.g., a tetracycline-inducible promoter, e.g., as described with transgenic tobacco plants containing the Avena sativa L. (oat) arginine decarboxylase gene (Masgrau (1997) Plant J. 11:465-473); or, a salicylic acid-responsive element (Stange (1997) Plant J. 11:1315-1324; Uknes et al., Plant Cell 5:159-169 (1993); Bi et al., Plant J. 8:235-245 (1995)).

Examples of useful inducible regulatory elements include copper-inducible regulatory elements (Mett et al., Proc. Natl. Acad. Sci. USA 90:4567-4571 (1993); Furst et al., Cell 55:705-717 (1988)); tetracycline and chlor-tetracycline-inducible regulatory elements (Gatz et al., Plant J. 2:397-404 (1992); Roder et al., Mol. Gen. Genet. 243:32-38 (1994); Gatz, Meth. Cell Biol. 50:411-424 (1995)); ecdysone inducible regulatory elements (Christopherson et al., Proc. Natl. Acad. Sci. USA 89:6314-6318 (1992); Kreutzweiser et al., Ecotoxicol. Environ. Safety 28:14-24 (1994)); heat shock inducible regulatory elements (Takahashi et al., Plant Physiol. 99:383-390 (1992); Yabe et al., Plant Cell Physiol. 35:1207-1219 (1994); Ueda et al., Mol. Gen. Genet. 250:533-539 (1996)); and lac operon elements, which are used in combination with a constitutively expressed lac repressor to confer, for example, IPTG-inducible expression (Wilde et al., EMBO J. 11:1251-1259 (1992)). An inducible regulatory element useful in the transgenic plants of the invention also can be, for example, a nitrate-inducible promoter derived from the spinach nitrite reductase gene (Back et al., Plant Mol. Biol. 17:9 (1991)) or a light-inducible promoter, such as that associated with the small subunit of RuBP carboxylase or the LHCP gene families (Feinbaum et al., Mol. Gen. Genet. 226:449 (1991); Lam and Chua, Science 248:471 (1990)).

C. Tissue-Specific Promoters

Alternatively, the plant promoter may direct expression of the PYR/PYL gene in a specific tissue (tissue-specific promoters). Tissue specific promoters are transcriptional control elements that are only active in particular cells or tissues at specific times during plant development, such as in vegetative tissues or reproductive tissues.

Examples of tissue-specific promoters under developmental control include promoters that initiate transcription only (or primarily only) in certain tissues, such as vegetative tissues, e.g., roots or leaves, or reproductive tissues, such as fruit, ovules, seeds, pollen, pistols, flowers, or any embryonic tissue, or epidermis or mesophyll. Reproductive tissue-specific promoters may be, e.g., ovule-specific, embryo-specific, endosperm-specific, integument-specific, seed and seed coat-specific, pollen-specific, petal-specific, sepal-specific, or some combination thereof. In some embodiments, the promoter is cell-type specific, e.g., guard cell-specific.

Other tissue-specific promoters include seed promoters. Suitable seed-specific promoters are derived from the following genes: MAC1 from maize (Sheridan (1996) Genetics 142:1009-1020); Cat3 from maize (GenBank No. L05934, Abler (1993) Plant Mol. Biol. 22:10131-1038); vivparous-1 from Arabidopsis (Genbank No. U93215); atmyc1 from Arabidopsis (Urao (1996) Plant Mol. Biol. 32:571-57; Conceicao (1994) Plant 5:493-505); napA from Brassica napus (GenBank No. J02798, Josefsson (1987) JBL 26:12196-1301); and the napin gene family from Brassica napus (Sjodahl (1995) Planta 197:264-271).

A variety of promoters specifically active in vegetative tissues, such as leaves, stems, roots and tubers, can also be used to express polynucleotides encoding PYR/PYL polypeptides (or RNAi or antisense or sense constructs). For example, promoters controlling patatin, the major storage protein of the potato tuber, can be used, see, e.g., Kim (1994) Plant Mol. Biol. 26:603-615; Martin (1997) Plant J. 11:53-62. The ORF13 promoter from Agrobacterium rhizogenes that exhibits high activity in roots can also be used (Hansen (1997) Mol. Gen. Genet. 254:337-343. Other useful vegetative tissue-specific promoters include: the tarin promoter of the gene encoding a globulin from a major taro (Colocasia esculenta L. Schott) corm protein family, tarin (Bezerra (1995) Plant Mol. Biol. 28:137-144); the curculin promoter active during taro corm development (de Castro (1992) Plant Cell 4:1549-1559) and the promoter for the tobacco root-specific gene TobRB7, whose expression is localized to root meristem and immature central cylinder regions (Yamamoto (1991) Plant Cell 3:371-382).

Leaf-specific promoters, such as the ribulose biphosphate carboxylase (RBCS) promoters can be used. For example, the tomato RBCS1, RBCS2 and RBCS3A genes are expressed in leaves and light-grown seedlings, only RBCS1 and RBCS2 are expressed in developing tomato fruits (Meier (1997) FEBS Lett. 415:91-95). A ribulose bisphosphate carboxylase promoters expressed almost exclusively in mesophyll cells in leaf blades and leaf sheaths at high levels, described by Matsuoka (1994) Plant J. 6:311-319, can be used. Another leaf-specific promoter is the light harvesting chlorophyll a/b binding protein gene promoter, see, e.g., Shiina (1997) Plant Physiol. 115:477-483; Casal (1998) Plant Physiol. 116:1533-1538. The Arabidopsis thaliana myb-related gene promoter (Atmyb5) described by Li (1996) FEBS Lett. 379:117-121, is leaf-specific. The Atmyb5 promoter is expressed in developing leaf trichomes, stipules, and epidermal cells on the margins of young rosette and cauline leaves, and in immature seeds. Atmyb5 mRNA appears between fertilization and the 16 cell stage of embryo development and persists beyond the heart stage. A leaf promoter identified in maize by Busk (1997) Plant J. 11:1285-1295, can also be used.

Another class of useful vegetative tissue-specific promoters are meristematic (root tip and shoot apex) promoters. For example, the “SHOOTMERISTEMLESS” and “SCARECROW” promoters, which are active in the developing shoot or root apical meristems, described by Di Laurenzio (1996) Cell 86:423-433; and, Long (1996) Nature 379:66-69; can be used. Another useful promoter is that which controls the expression of 3-hydroxy-3-methylglutaryl coenzyme A reductase HMG2 gene, whose expression is restricted to meristematic and floral (secretory zone of the stigma, mature pollen grains, gynoecium vascular tissue, and fertilized ovules) tissues (see, e.g., Enjuto (1995) Plant Cell. 7:517-527). Also useful are kn1-related genes from maize and other species which show meristem-specific expression, see, e.g., Granger (1996) Plant Mol. Biol. 31:373-378; Kerstetter (1994) Plant Cell 6:1877-1887; Hake (1995) Philos. Trans. R. Soc. Lond. B. Biol. Sci. 350:45-51. For example, the Arabidopsis thaliana KNAT1 promoter (see, e.g., Lincoln (1994) Plant Cell 6:1859-1876).

One of skill will recognize that a tissue-specific promoter may drive expression of operably linked sequences in tissues other than the target tissue. Thus, as used herein a tissue-specific promoter is one that drives expression preferentially in the target tissue, but may also lead to some expression in other tissues as well.

In another embodiment, the PYR/PYL polynucleotide is expressed through a transposable element. This allows for constitutive, yet periodic and infrequent expression of the constitutively active polypeptide. The invention also provides for use of tissue-specific promoters derived from viruses including, e.g., the tobamovirus subgenomic promoter (Kumagai (1995) Proc. Natl. Acad. Sci. USA 92:1679-1683; the rice tungro bacilliform virus (RTBV), which replicates only in phloem cells in infected rice plants, with its promoter which drives strong phloem-specific reporter gene expression; the cassava vein mosaic virus (CVMV) promoter, with highest activity in vascular elements, in leaf mesophyll cells, and in root tips (Verdaguer (1996) Plant Mol. Biol. 31:1129-1139).

VIII. Production of Transgenic Plants

As detailed herein, the present invention provides for transgenic plants comprising recombinant expression cassettes either for expressing PYR/PYL proteins in a plant or for inhibiting or reducing endogenous PYR/PYL expression. Thus, in some embodiments, a transgenic plant is generated that contains a complete or partial sequence of an endogenous PYR/PYL encoding polynucleotide, either for increasing or reducing PYR/PYL expression and activity. In some embodiments, a transgenic plant is generated that contains a complete or partial sequence of a polynucleotide that is substantially identical to an endogenous PYR/PYL encoding polynucleotide, either for increasing or reducing PYR/PYL expression and activity. In some embodiments, a transgenic plant is generated that contains a complete or partial sequence of a polynucleotide that is from a species other than the species of the transgenic plant. It should be recognized that transgenic plants encompass the plant or plant cell in which the expression cassette is introduced as well as progeny of such plants or plant cells that contain the expression cassette, including the progeny that have the expression cassette stably integrated in a chromosome.

A recombinant expression vector comprising a PYR/PYL coding sequence driven by a heterologous promoter may be introduced into the genome of the desired plant host by a variety of conventional techniques. For example, the DNA construct may be introduced directly into the genomic DNA of the plant cell using techniques such as electroporation and microinjection of plant cell protoplasts, or the DNA construct can be introduced directly to plant tissue using ballistic methods, such as DNA particle bombardment. Alternatively, the DNA construct may be combined with suitable T-DNA flanking regions and introduced into a conventional Agrobacterium tumefaciens host vector. The virulence functions of the Agrobacterium tumefaciens host will direct the insertion of the construct and adjacent marker into the plant cell DNA when the cell is infected by the bacteria. While transient expression of PYR/PYL is encompassed by the invention, generally expression of construction of the invention will be from insertion of expression cassettes into the plant genome, e.g., such that at least some plant offspring also contain the integrated expression cassette.

Microinjection techniques are also useful for this purpose. These techniques are well known in the art and thoroughly described in the literature. The introduction of DNA constructs using polyethylene glycol precipitation is described in Paszkowski et al. EMBO J. 3:2717-2722 (1984). Electroporation techniques are described in Fromm et al. Proc. Natl. Acad. Sci. USA 82:5824 (1985). Ballistic transformation techniques are described in Klein et al. Nature 327:70-73 (1987).

Agrobacterium tumefaciens-mediated transformation techniques, including disarming and use of binary vectors, are well described in the scientific literature. See, for example, Horsch et al. Science 233:496-498 (1984), and Fraley et al. Proc. Natl. Acad. Sci. USA 80:4803 (1983).

Transformed plant cells derived by any of the above transformation techniques can be cultured to regenerate a whole plant that possesses the transformed genotype and thus the desired phenotype such as enhanced drought-resistance. Such regeneration techniques rely on manipulation of certain phytohormones in a tissue culture growth medium, typically relying on a biocide and/or herbicide marker which has been introduced together with the desired nucleotide sequences. Plant regeneration from cultured protoplasts is described in Evans et al., Protoplasts Isolation and Culture, Handbook of Plant Cell Culture, pp. 124-176, MacMillilan Publishing Company, New York, 1983; and Binding, Regeneration of Plants, Plant Protoplasts, pp. 21-73, CRC Press, Boca Raton, 1985. Regeneration can also be obtained from plant callus, explants, organs, or parts thereof. Such regeneration techniques are described generally in Klee et al. Ann. Rev. of Plant Phys. 38:467-486 (1987).

One of skill will recognize that after the expression cassette is stably incorporated in transgenic plants and confirmed to be operable, it can be introduced into other plants by sexual crossing. Any of a number of standard breeding techniques can be used, depending upon the species to be crossed.

The expression cassettes of the invention can be used to confer drought resistance on essentially any plant. Thus, the invention has use over a broad range of plants, including species from the genera Asparagus, Atropa, Avena, Brassica, Citrus, Citrullus, Capsicum, Cucumis, Cucurbita, Daucus, Fragaria, Glycine, Gossypium, Helianthus, Heterocallis, Hordeum, Hyoscyamus, Lactuca, Linum, Lolium, Lycopersicon, Malus, Manihot, Majorana, Medicago, Nicotiana, Oryza, Panieum, Pannesetum, Persea, Pisum, Pyrus, Prunus, Raphanus, Secale, Senecio, Sinapis, Solanum, Sorghum, Trigonella, Triticum, Vitis, Vigna, and, Zea. In some embodiments, the plant is selected from the group consisting of rice, maize, wheat, soybeans, cotton, canola, turfgrass, and alfalfa. In some embodiments, the plant is an ornamental plant. In some embodiment, the plant is a vegetable- or fruit-producing plant.

Those of skill will recognize that a number of plant species can be used as models to predict the phenotypic effects of transgene expression in other plants. For example, it is well recognized that both tobacco (Nicotiana) and Arabidopsis plants are useful models of transgene expression, particularly in other dicots.

The plants of the invention have either enhanced or reduced abscisic acid sensitivity compared to plants are otherwise identical except for expression of PYR/PYL. Abscisic acid sensitivity can be monitored by observing or measuring any phenotype mediated by ABA. Those of skill in the art will recognize that ABA is a well-studied plant hormone and that ABA mediates many changes in characteristics, any of which can be monitored to determined whether ABA sensitivity has been modulated. In some embodiments, modulated ABA sensitivity is manifested by altered timing of seed germination or altered stress (e.g., drought) tolerance.

Drought resistance can assayed according to any of a number of well-known techniques. For example, plants can be grown under conditions in which less than optimum water is provided to the plant. Drought resistance can be determined by any of a number of standard measures including turgor pressure, growth, yield, and the like. In some embodiments, the methods described in the Example section, below can be conveniently used.

EXAMPLES

The following examples are offered to illustrate, but not to limit the claimed invention.

Example 1: PYR/PYL Modulation of ABA Signaling

Unlike biochemical screens for ABA-binding proteins, genetic analyses focused on ABA perception have not yet identified proteins resembling receptors, suggesting that the receptor(s) may be functionally redundant, have overlapping functions or cannot mutate to yield viable gametes or seedlings (P. McCourt, Annual Review of Plant Physiology and Plant Molecular Biology 50, 219 (1999)). As a complementary approach, we have pursued a chemical genetic strategy in plants (Y. Zhao et al., Nat Chem Biol 3, 716 (2007)). This approach can be advantageous for organisms with highly redundant genomes, because the variable selectivity of small molecules can cause phenotypes not revealed by single gene mutations (N. Raikhel, M. Pirrung, PLANT PHYSIOLOGY 138, 563 (2005); S. Cutler, P. McCourt, Plant Physiol. 138, 558 (2005)). For example an antagonist with low selectivity can perturb the function of an entire protein family (as seen with microtubule antagonists), while an agonist with high selectivity may illuminate the function of an individual member of normally redundant receptors, as we describe here with pyrabactin 3 (FIG. 1A).

Pyrabactin is a Seed-Selective ABA Agonist

As part of an earlier effort, we identified a germination inhibitor named pyrabactin (Y. Zhao et al., Nat Chem Biol 3, 716 (2007)). By examining the sensitivity of multiple wild accessions to pyrabactin, we found that the Cold Spring Harbor Lab wild type, which is ABA-hypersensitive and hyperdormant, is also hypersensitive to pyrabactin, but not an inactive analog apyrabactin 4 (FIG. 1A). This suggested that pyrabactin might act through the ABA response pathway. To test this hypothesis, we examined the pyrabactin sensitivity of mutant lines with altered ABA signaling, biosynthesis or gibberellic acid (GA) perception. We found that ABA perception, but not biosynthesis, mutants affect pyrabactin sensitivity (FIG. 1B). Additionally an rgl2-1 mutant line, which does not require GA during germination (S. Lee et al., Genes Dev. 16, 646 (Mar. 1, 2002, 2002)), has normal pyrabactin sensitivity (FIG. 1B). Together, these observations suggest that pyrabactin inhibits germination by activating the ABA signaling pathway, rather than by modulating ABA or GA biosynthesis.

We next performed microarray experiments to evaluate the similarity of the transcriptional responses induced by ABA and pyrabactin treatments. For microarray, tissue was prepared and RNA extracted from Columbia wild type seeds sown on 0.5×MS media (˜2500 seeds per 150 mm plate) containing either 1 μM ABA, 25 μM pyrabactin, 25 μM 2,4-Dinitrophenol (DNP), 1 μM cycloheximide, 2 μM methotrexate or 1% DMSO control plates (all chemicals are dissolved in DMSO). The concentrations utilized for these experiments were normalized for germination inhibition activity by dose curve analyses, i.e. the amount of both compounds required to ensure 100% inhibition of germination when scored 3 days post-imbibition. ABA (±stereoisomers), DNP, cycloheximide and methotrexate were purchased from Sigma Aldrich. Seeds were stratified for 4 days and then incubated in the dark at room temperature for 24 hours. Seeds were collected and frozen in liquid nitrogen, then ground to fine powder form with frozen mortar and pestle, after which total RNA was extracted using the RNAqueous kit (Ambion; Austin, USA) for the first set of replicate samples. Subsequent RNA extractions were performed using the phenol-chloroform extraction protocol, as described by (Y. Suzuki, T. Kawazu, H. Koyama, Biotechniques, 37, 542 (October, 2004)). For each sample of total RNA, 1 μl of RNA was quantified in 99 μl 10 mM Tris-Cl (pH 7.4) by the GeneQuant RNA/DNA Calculator (GE Healthcare Bio-Sciences Corp.; New Jersey, USA), where absorbance measurements were taken at 260 nm and 280 nm. Purity of the RNA was assessed by OD₂₆₀/OD₂₈₀ ratios (only ratios between 1.7 and 2.2 were used), while quality of the RNA was assessed by gel electrophoresis. Total RNA samples were converted to biotin-labeled cRNA using oligo-dT priming as described by the manufacturer (Enzo kit; Affymetrix; Santa Clara, USA) and hybridized to 22K ATH1 Affymetrix microarrays at the CAGEF (University of Toronto). Duplicate biological replicate samples were hybridized for DNP, cycloheximide and methotrexate, triplicate for control and quadruplicate samples were hybridized for, pyrabactin and ABA treatments. Probe sets with expression signals called present or marginal by the statistical algorithms applied to the microarrays as described as described for the GCOS/MAS5.0 algorithm (Affymetrix; Santa Clara, USA). Significance Analysis of Microarrays was used to identify probe sets that are significantly regulated by treatments using unlogged data, with a false discovery rate (FDR) at about 5%. Average transcript levels were compared to control values to compute fold-change, which was in turn log₂ transformed and used to compute Pearson Correlation Coefficients between experiments.

We first examined seeds treated with both compounds for 24 hours. Due to inhibitory effects on seedling development, any two germination inhibitors will share some common responses; we therefore used a previously defined set of germination responsive transcripts (G. W. Bassel et al., Plant Physiol 147, 143 (2008)) to minimize developmental effects in our comparisons. 1225 probe sets were identified as responsive to either ABA or pyrabactin using SAM analysis (V. G. Tusher, R. Tibshirani, G. Chu, Proc. Nat'l. Acad. Sci. USA 98, 5116 (2001)), after removal of 403 germination-regulated transcripts. Scatter plots comparing a probe's responsiveness to pyrabactin and ABA demonstrate highly correlated responses (r=0.98; FIG. 1C), consistent with the hypothesis that pyrabactin activates ABA signaling. As a control, we also profiled the effects of the three germination inhibitors (G. W. Bassel et al., Plant Physiol 147, 143 (2008)) cycloheximide, methotrexate and 2,4-dinitrophenol, and observed much weaker transcript-response correlations when compared to ABA treatments (r=0.36, 0.73 and 0.81 respectively; cycloheximide shown in FIG. 1D). This demonstrates that an indirect developmental effect is not sufficient to account for the ABA-like transcriptional effects of pyrabactin.

To establish if pyrabactin is a general ABA agonist, we examined its activity in seedlings treated with either compound for 24 hours, which showed that pyrabactin induces a greatly muted ABA response (r=0.72) in seedling tissues (FIG. 1E). For seedling microarray experiments, Columbia wild type seeds were surface sterilized and sown on 0.5×MS, 0.6% (w/v) agar plates (15 mg seeds, 25 ml media per 150 mm plate), followed by stratification for 4 days at 4° C. and grown under 24-h light at room temperature for 9 days. 40 seedlings were then transferred to either DMSO control, 10 μM ABA or 33 μM pyrabactin plates and returned to the growth environment for another 24 hours, after which total RNA was extracted using the method described above. Triplicate samples were hybridized per treatment. The concentrations used for seedling experiments were based on concentrations of ABA or pyrabactin that are required to inhibit primary root growth by equivalent amounts, i.e. they were normalized to a measure of bioactivity. In these experiments, 57 transcripts responded significantly to both pyrabactin and ABA, suggesting that pyrabactin can induce aspects of an ABA response in seedlings. However, since 3021 transcripts in this experiment showed a significant response to ABA, but not pyrabactin, we conclude that pyrabactin acts with greater selectivity for the seed pathway in comparison to ABA. Pyrabactin does agonize ABA responses in vegetative tissues.

PYR1, a START Protein, is Necessary for Pyrabactin Action

To dissect pyrabactin's mechanism of action, we isolated a collection of 16 pyrabactin insensitive mutant lines from a screen of ˜450,000 EMS mutagenized M2 seed. Surface sterilized EMS seeds were sown on 0.33×MS media containing 25 μM pyrabactin (50 mg seeds per 150 mm plate). Seeds were stratified for 4 days at 4° C. and grown under constant light for 4 days at room temperature, after which plates were scored for mutants resistant to the germination inhibition effect of pyrabactin. Seedlings with fully expanded cotyledons were considered resistant, and all mutants identified as resistant were then retested in the next generation to identify true mutants. The strong pyr1-7 allele was used to map Pyr1 using a mapping population of ˜400 plants (created from progeny of a cross to Ler). This delimited Pyr1 to an ˜150 Kb interval containing 12 genes. The identity of Pyr1 was first suggested after sequencing the 12 genes in this interval and identifying a stop codon in At4g17870 (Pyr1). After this, the Pyr1 coding sequence for 14 of the 16 mutations isolated were sequenced and 12 independent strains were determined by map based cloning and sequencing to contain mutations in the same locus, PYRABACTIN RESISTANCE 1 (Pyr1). Pyr1 encodes a protein that is a member of the START/Bet v 1 superfamily whose members share a conserved ligand-binding helix-grip architecture (L. M. Iyer, E. V. Koonin, L. Aravind, Proteins: Structure, Function, and Genetics 43, 134 (2001); C. Radauer, P. Lackner, H. Breiteneder, BMC Evol Biol 8, 286 (2008)). PYR1 resides in a Bet v 1 subfamily similar to bacterial polyketide synthases/cyclases and other non-enzymatic proteins (C. Radauer, P. Lackner, H. Breiteneder, BMC Evol Biol 8, 286 (2008)). There are 13 genes in the Arabidopsis genome that show significant similarity to Pyr1 in BLAST searches, which we have named PYL1-PYL13 (for PYR1-Like; their AGIs are listed in Table 1). The pyrabactin insensitive pyr1 alleles we isolated are predicted to produce a variety of defects in PYR1, including truncations and non-conservative amino acid substitutions (FIG. 2A). Transformation of a 35S::GFP-PYR1 expression construct into the strong pyr1-1 mutant line restores seed pyrabactin sensitivity (FIG. 2C), which provides further support that PYR1 is necessary for pyrabactin action. None of the pyr1 alleles isolated show strong ABA insensitivity, which as we describe below, is explained by the action of redundant Pyr1 relatives (including, but not limited to Pyl1, 2, 4). By querying public microarray databases (M. Schmid et al., Nat Genet 37, 501 (2005); K. Nakabayashi, M. Okamoto, T. Koshiba, Y. Kamiya, E. Nambara, Plant J 41, 697 (March, 2005); H. Goda et al., Plant J 55, 526 (August, 2008); D. Winter et al., PLoS ONE 2, e718 (2007); Y. Yang, A. Costa, N. Leonhardt, R. S. Siegel, J. I. Schroeder, Plant Methods 4, 6 (2008)) it is clear that Pyr1 mRNA is expressed highly in seeds and guard cells and is responsive to ABA (FIG. 2B), consistent with a role for PYR1 in ABA signaling.

TABLE 1 Members of PYR/PYL family and corresponding Arabidopsis Genome Initative (AGI) annotations. Gene AGI Pyr1 AT4G17870 Pyl1 AT5G46790 Pyl2 AT2G26040 Pyl3 AT1G73000 Pyl4 AT2G38310 Pyl5 AT5G05440 Pyl6 AT2G40330 Pyl7 AT4G01026 Pyl8 AT5G53160 Pyl9 AT1G01360 Pyl10 AT4G27920 Pyl11 AT5G45860 Pyl12 AT5G45870 Pyl13 AT4G18620 PYR/PYL Proteins Bind PP2Cs in Response to ABA

Given that PYR1 is necessary for pyrabactin action and is a predicted ligand-binding protein, we hypothesized that pyrabactin agonizes ABA signaling by inducing a protein-protein interaction between PYR1 and a downstream effector. To test this, ˜2 million prey cDNA clones were screened against a PYR1 Y2H bait construct on media containing 10 μM pyrabactin. To create the PYR1 Y2H bait construct, the Pyr1 open reading frame was PCR amplified from genomic DNA and cloned to pGem-T easy vector (Promega). After sequence confirmation, the Pyr1 ORF was then cloned in-frame between EcoRI and SalI sites of the pBD-GAL4 Cam vector (Stratagene) and transformed into yeast strain Y190. For the screen, an etiolated seedling cDNA library (J. Kim, K., Harter, A., Theologis, Proc Natl Acad Sci USA 94, 11786 (Oct. 28, 1997)) (ABRC stock CD4-22) was used. The cDNA library was first converted from phage to plasmid DNA, yielding 7.6×10⁷ transformants. Plasmid DNA prepared from library was then used to transform Y190 as described in the GAL4 Two-Hybrid system manual (Stratagene). For each screen, 40 μg of prey plasmid was transformed into 1 ml of competent Y190 cell harboring bait construct and then grown on SD agar plates lacking His, Leu, and Trp, but containing 15 mM 3-AT and 10 μM pyrabactin. After 4 days incubation at 30° C., well-grown colonies were rescued and interactions validated using filter lift assay or chloroform-agarose overlay method and X-Gal staining. This identified two pyrabactin-dependent hits which sequencing determined encoded cDNAs for the PP2C HAB1, a close relative of the well-characterized ABA response factor ABI1 (A. Saez et al., The Plant Journal 37, 354 (2004); N. Leonhardt et al., THE PLANT CELL 16, 596 (2004)). Next, Y2H strains expressing an AD-HAB1 fusion protein and a BD-PYR1 fusion protein were grown on plates and tested for interactions in response to various compounds, all at 10 μM except for epi-brassinolide (50 nM) and dimethyl sulfoxide (DMSO) (carrier solvent, 1%). When the pyrabactin-responsive PYR1-HAB1 Y2H strains were tested on (+)-ABA, strong interactions were observed by X-gal stain, but neither (−)-ABA, kinetin, 2,4-D, Gibberellic acid (GA), epi-brassinolide (BR), methyl jasmonate (meJA) or apyrabactin showed activity (FIG. 3A). Thus, PYR1 interacts with HAB1 in a (+)-ABA dependent fashion.

To see if ABA and pyrabactin responsiveness is unique to PYR1, we tested 11 of the 13 PYL proteins as described above, using Y2H strains expressing an AD-HAB1 fusion protein and a BD-PYR/PYL fusion protein (listed at the left of FIG. 3A). BD-PYR/PYL fusion proteins were constructed in the same manner as for BD-PYR1 above. This assay showed that PYL1-PYL4 interact with HAB1 in an ABA-stimulated manner (FIG. 3A). Ligand-selective interactions are also observed for pyrabactin, which promotes interactions between HAB1 and PYR1, PYL1, or PYL3 (FIG. 3A). Of these, only Pyr1 is highly transcribed in seeds, which likely explains why mutations in Pyr1 cause the seeds to be insensitive to pyrabactin. PYL2-PYL4 respond to both (+)-ABA and (−)-ABA (FIG. 3A), suggesting that they could be involved in both (+) and (−)-ABA responses. Notably, the remaining PYLs tested in the yeast two hybrid assay show constitutive interactions with HAB1, suggesting they may have different thresholds for interaction with the PP2Cs from PYR1 and PYLs 1 to 4. However the interactions of PYLs 5-12 with the PP2Cs are indicative that the entire protein family is likely to share a similar mechanism of action involving PP2C modulation, as we describe below. Thus, we conclude that entire family modulates ABA responses via PP2C interactions.

To investigate the ABA/pyrabactin responses further, we used the Y2H assay as described above to examine three substitution mutant proteins that cause strong pyrabactin insensitive phenotypes in plants. Two of the mutants tested, PYR1^(S152L) and PYR1^(P88S), greatly reduce ABA induced PYR1-HAB1 interactions, while the PYR1^(R157H) mutation does not affect the interaction (FIG. 3B). HAB1 possesses genetic redundancy with ABI1, ABI2 and other related PP2Cs (T. Yoshida et al., PLANT PHYSIOLOGY 140, 115 (2006)). We therefore tested ABI1 and ABI2 in the Y2H assay, using publicly available sequence validated cDNAs for ABI1 and ABI2 (C104649, and U24491 respectively). We observed that PYR1 interacts with wild type ABI1 and ABI2, but not the ABA insensitive protein ABI2^(G168D) encoded by abi2-1 (FIG. 3C). Thus, residues important to PYR1 and PP2C function in planta are important for the ABA response reconstituted in yeast. These in vivo interactions between PYR1 and PP2C likely occur in the cytoplasm and nucleoplasm, as suggested by the localization pattern observed for GFP-PYR1 (FIG. 4).

PYR/PYL Proteins Act Redundantly in ABA Signaling

To examine whether the ABA-responsive PYL proteins act redundantly with PYR1 in ABA signaling, we isolated homozygous insertion alleles for PYL1, 2 and 4 from public insertion-allele collections (seed strains=Salk_054640, GT_2864, Sail_517_C08 respectively) (J. M. Alonso et al., Science 301, 653 (2003); A. Sessions et al., THE PLANT CELL 14, 2985 (2002); V. Sundaresan et al., Genes and Development 9, 1797 (1995)). The homozygous insertion lines and pyr1-1 were crossed to create pyr1-1:pyl2-1 and pyl1-1:pyl4-1 heterozygous lines, which were then crossed to one another. ˜70 progeny from this cross were genotyped by PCR to identify lines heterozygous for all 4 mutations, and 2 plants were identified. To assess if these lines segregated ABA insensitive plants, the F2 seed from a quadruple heterozygous plant were germinated on 0.7 μM (+)-ABA. Extensive variation in germination and growth was observed, and the most ABA-resistant seedlings were selected from ˜1000 seed and genotyped by PCR and sequencing. None of the homozygous single mutant parents showed marked ABA insensitivity, but both a triple (pyr1-1, pyl1-1, pyl4-1) and quadruple (pyr1-1, pyl1-1, pyl2-1, pyl4-1) mutant line showed ABA insensitivity. The root and germination responses of the quadruple and triple mutants lines were examined in comparison to abi1-1, the strongest ABA-insensitive mutant isolated to date. For germination assays, seeds were stratified on plates containing (+)-ABA on 0.33×MS for 4 days at 4° C. and then germinated at 23° C. in the dark for 3 days at 90% RH. Seeds showing radicals ½ seed length or longer were scored as positive for germination. To investigate root growth, seeds were allowed to first germinate on MS plates after 4 days of stratification and then transferred to germinate at 23° C. in darkness at 90% RH. 48 hours post imbibition, seedlings showing radical emergence were transferred to (+)-ABA containing or control plates, grown vertically for 4 additional days in the dark and then new root growth measured. In germination assays, the quadruple mutant was more insensitive than the triple, but both exhibited a weaker phenotype than abi1-1 (FIG. 5A). In root growth assays, the quadruple and triple mutant lines both showed greater ABA insensitivity than abi1-1 (FIG. 5B). The quadruple mutant line also exhibits defects in ABA-induced gene expression. Quantitative RT-PCR experiments were conducted as described previously (H. Fujii, et al., Plant Cell, 19, 485 (2007)) using taqman probes identical to those described by Fujii et al. Briefly, 7 day old seedlings grown under continuous illumination on 0.3×MS plates were transferred to 0.3×MS media containing carrier solvent (0.1% DMSO) or 100 μM (+)-ABA for 5 hours, after which total RNA was isolated using Qiagen plant RNeasy isolation kit. 5 μg total RNA was used per 20 μL first strand cDNA synthesis reaction using SuperScript Reverse Transcriptase. The reactions were diluted to 100 μl with TE and 1.5 μl of this was used in 15 μL qRT-PCR reactions using taqman probes described previously (6). Values shown are the average of triplicate measurements. Quadruple mutants exhibit decreased transcription of the ABA-responsive genes RD29 (FIG. 2D), NCED3 (FIG. 2E), and P5CS1 (FIG. 2E) in the presence of (+)-ABA. These experiments show that PYL1, PYL2 and PYL4 function redundantly with PYR1 in the control of ABA-induced gene expression and germination and root responses to ABA.

In Vitro Reconstitution of ABA Perception: ABA and PYR1 Inhibit PP2C Activity

To explore the functional implications of the PYR1-PP2C interaction, we examined if an ABA response could be reconstituted in vitro. Recombinant GST-HAB1, GST-ABI1 and GST-ABI2 were expressed in E. coli and tested for ligand-dependent interactions with 6×His-PYR1 in pull-down assays. Purified 6×His-PYR1 and GST-HAB1 (20 and 100 μg respectively, 8 μM PYR1 final concentration), were combined in 100 μl TBS containing 10 μM (+)-ABA or 1% DMSO for negative control. The reaction was incubated for 90 minutes at RT and 5 μl of PrepEase (USB) His-tagged protein purification resin was added. The resin and reaction mixture was incubated 30 min at RT with gentle shaking at 5 min intervals. The resin was washed five times with TBS containing 10 μM (+)-ABA. After the final wash, the bound protein was eluted in 20 μl SDS-PAGE buffer, boiled for 5 minutes and centrifuged. 5 μl of eluate was analyzed on SDS-PAGE. For pull-downs with ABI1 and ABI2, crude lysates were used in a similar method, except purified PP2C was replaced with cleared E. coli lysates. The amount of lysate added was determined by SDS-page analysis to yield ˜100 μg PP2C, such that the same stoichiometry was used as in assays using purified proteins. We found that both (+)-ABA and pyrabactin promote PP2C interactions with PYR1; however PYR1^(P88S) is insensitive in this assay (FIG. 6A).

Since ABI1 and relatives are negative regulators of the ABA signaling pathway, we hypothesized that the function of the ABA-promoted PYR1-PP2C interaction was to inhibit phosphatase activity and remove a negative input into the pathway, which would then promote signaling. To test this hypothesis, we examined the effects of (+)-ABA on PP2C enzyme kinetics using recombinant GST-HAB1, 6×His-PYR1 or 6×His-PYR1^(P88S) using the phosphatase substrate pNPP. The ORF of Arabidopsis HAB1 was amplified by PCR from a pUni clone obtained from the ABRC and cloned into pGex-2T to create a GST-HAB1 fusion protein. Both constructs were transformed into BL21[DE3]pLysS. For expression, cells harboring pGex-GST-HAB1 were grown overnight in 20 ml LB and then inoculated to 700 ml media containing 1 mM MnCl₂ and continued incubation with shaking at RT for 8 hr. Protein expression was then induced by addition of IPTG to final concentration of 0.5 mM, and cells were cultured overnight at RT. Cells were then harvested by centrifugation at 4500 rpm for 20 min, resuspended in 10 ml TBS containing 10 mM MnCl₂. Cells were stored at −80° C. To prepare cleared lysates, cells were freeze-thawed twice and the lysate's viscosity reduced by shearing. The lysate was then spun at 12000×g for 10 min to yield the final cleared lysates. This was applied to 1 ml of immobilized glutathione column, washed with 20 ml of TBS and bound protein then eluted with 20 mM reduced glutathione. The eluate was dialyzed against TBS containing 10 mM MnCl₂. MnCl₂ was used through purification steps and found to be critical for recovery of highly active HAB1 protein, as described previously for other PP2Cs (C. C. Fjeld, J. M. Denu, J Biol Chem, 274, 20336 (Jul. 16, 1999)). The PYR1 and PYR1^(P88S) coding sequences were amplified by PCR from genomic DNA of wild type or the pyr1-3 mutant respectively and cloned into pET28 to produce various 6×His-PYR1 proteins, which were validated by sequencing. For 6×His-PYR1 and 6×His-PYR1^(P88S) protein expressions, 20 ml of an overnight culture was inoculated to 700 ml LB and was grown for additional 3 hours at 37° C. with shaking Protein expression was induced by addition of IPTG to 1 mM. Cells were harvested 5 hr later by centrifugation for 15 min at 5000×g and the pellet was resuspended in 5 ml of the Buffer A (50 mM NaH₂PO₄, 300 mM NaCl) containing 10 mM imidazole, pH 8.0). Cells were stored at −80° C. before purification. After thawing, cells were sonicated on ice five times for 30 sec with 30 sec resting intervals. A cleared lysate was obtained after centrifugation at 12,000×g for 10 min and applied to 1 ml of Ni-NTA column (Qiagen) and washed with 20 column volumes of Buffer A containing 30 mM imidazole. Bound protein was eluted with 10 ml of Buffer A with 100 mM imidazole. The elutate was dialyzed against TBS. For the pNPP assay, initial reaction velocities for GST-HAB1 were conducted using the synthetic phosphatase substrate pNPP. Reactions contained 1 μM GST-HAB1, 1.5 μM 6×His-PYR1 or 6×His-PYR1^(P88S) and a reaction buffer consisting of 33 mM Tris-OAc, pH 7.9, 66 mM KOAc, 0.1% BSA, 25 mM Mg(OAc)₂, 50 mM pNPP and varying (+)-ABA concentrations. Reactions were initiated by the addition of assay buffer to protein/ABA mixes. Immediately after mixing, reactions were monitored for hydrolysis of pNPP at A405 t˜10 second intervals over 20 minutes using a Wallac plate reader. Reaction progressions were plotted, initial velocities calculated and converted to specific activities using a standard curve for 4-nitrophenol made in the same buffer system volumes/plate reader used for enzymatic reaction measurements. These experiments show that (+)-ABA acts as a potent inhibitor of HAB1 phosphatase activity (IC₅₀=0.18 μM) in the presence of PYR1, but not PYR1^(P88S) (FIG. 6B).

Similarly, ABA displays saturable inhibition of HAB1 PP2C activity in the presence of recombinant PYL4. A PYL4 6×His-tagged (SEQ ID NO:141) protein was constructed using a public pUni clone. This was recombined into the His-tagged expression vector pHB3. The construct was expressed in BL21[DE3] pLysS as described above for PYR1, but the protein formed inclusion bodies, which were solubilized in Buffer B+8 M urea, prior to purification. The protein was purified under denaturing conditions using Ni-NTA resin according to manufacturer's instructions. After binding of protein to resin, the column was washed with 20 volume of Buffer B (pH6.3) and protein eluted using Buffer A (pH4.5). The eluted protein was dialyzed slowly from TBS containing 2 M urea, 10 mM DTT into TBS containing 1 mM DTT over three days, gradually lowering the urea concentration over time. The activity of refolded PYL4 was validated using in vitro pull down assays developed for PYR1, where it was shown that PYL4 binds HAB1 in response to ABA. For the PP2C assays, recombinant PYL4 (refolded from inclusion bodies) and HAB1 were used. When phosphatase activity was measured for GST-HAB1 using the phosphatase substrate pNPP, we found that (+)-ABA inhibits HAB1 phosphatase activity in the presence of PYL4 (FIG. 6C). Thus, PP2C inhibition is a primary ABA-response that can be reconstituted in vitro with only proteins.

DISCUSSION

We have shown that PYR1 has the properties expected of an ABA receptor and that it binds to and inhibits PP2C activity when ligand is present. In contrast to previously identified ABA binding proteins (P. McCourt, R. Creelman, Current Opinion in Plant Biology 11, 474 (2008)), PYR1 interacts directly with core components of the ABA signaling pathway. ABI1 interacts with at least one positively acting factor in the ABA response pathway (R. Yoshida et al., Journal of Biological Chemistry 281, 5310 (2006)). It may therefore be that the role of ABI1/AHG1 class PP2Cs in the absence of a signal is to repress the action of positively acting factors. In this model, ABA functions at the apex of a negative regulatory pathway and the PP2Cs control signal output through their direct targets. This imbues the PP2Cs with a critical role in controlling the selectivity of signal-output, which could explain the extensive diversification of the PP2C gene family in plants relative to animals (A. Schweighofer, H. Hirt, I. Meskiene, Trends in Plant Science 9, 236 (2004)). Based on the interaction of PP2Cs with SnRK2 proteins and the critical role of SnRK2s for ABA signaling (FIG. 7) we have proposed the following model for ABA action in which ABA and PYR/PYLs inhibit the PP2Cs, which in turn relieves repression of positive factors, such as the SnRK2s. This in turn allows the positive SnRK2 kinases to modulate activity of downstream factors via phosphorylation.

Our experiments show that at least 12 of the 14-members in the PYR/PYL gene family bind to PP2Cs, and some members such as PYL2s, 3 and 4 enable yeast cells to respond to the unnatural stereoisomer (−)-ABA. We believe the entire family are ABA receptors and that some may also be (−)-ABA receptors. This hypothesis is consistent with earlier conclusions that both stereoisomers act through the same signaling pathway (E. Nambara et al., Genetics 161, 1247 (July, 2002)).

PYR1 is unable to bind to the proteins encoded by abi1-1 and abi2-1, which both contain mutations in glycines near one of the two conserved PP2C metal binding sites. These mutations lower, but do not abolish, PP2C activity (F. Gosti et al., The Plant Cell 11, 1897 (1999); N. Robert, S. Merlot, V. N'Guyen, A. Boisson-Dernier, J. I. Schroeder, FEBS Letters 580, 4691 (2006)) and a second site mutation that completely abolishes abi1-1's catalytic activity suppresses its dominant phenotype (F. Gosti et al., The Plant Cell 11, 1897 (1999)). Together with our observations on defective PYR1 interactions, these data suggest a model where the dominance of the abi1-1 and abi2-1 mutations stems from their ability to escape negative regulation by the PYR/PYL proteins. In this model, a major function of ABA is to lower ABI1/AHG1 class PP2C activity via PYR/PYL proteins, but this does not occur properly in the abi1-1 and abi2-1 mutant lines, which retain sufficient PP2C activity after ABA perception to disrupt signal transduction.

The regulation of PP2Cs is poorly understood with respect to other phosphatase classes, which is surprising given their important roles in mammals, worms, flies and yeast (G. Lu, Y. Wang, Clinical and Experimental Pharmacology and Physiology 35, 107 (2008)). Our observations provide a new mechanism for receptor-mediated regulation of PP2C activity. Although the precise mechanism of PP2C inhibition by PYR1 is unknown, the PYR1^(R157H) mutation is able to separate ligand perception from downstream functions in vivo. This residue may therefore play a critical role in steps that lead to inhibition of PP2C activity after signal perception. Regardless of the precise details of PP2C inhibition, the novel regulatory mechanism discovered suggests that it may be worth investigating receptor-mediated PP2C regulation in other models, given the dearth of regulatory factors for these vital phosphatases.

The ABA signaling pathway has been the subject of genetic analysis for almost 30 years, but the PYR/PYL proteins never emerged as factors necessary for an ABA response in genetic screens. In hindsight, this is now obvious due to the necessity of a triple mutant to observe an ABA-insensitive phenotype. When using pyrabactin as a synthetic agonist of the pathway however, Pyr1 was identified with ease. The reason for this is due to pyrabactin's selectivity for a subset of the entire receptor family, which enabled us to bypass the genetic redundancy that obscures an ABA phenotype in single mutant lines. Thus, our results demonstrate the power of the chemical genetic approach to reveal phenotypes for normally redundant genes. Because plant genomes are highly redundant, we expect that small molecule approaches will provide a powerful addendum to classical genetic analysis.

Example 2: Screens for Agonists of PYR/PYL

We next investigated whether other compounds besides ABA and pyrabactin could act as agonists of PYR/PYL proteins. Yeast two hybrid strains expressing ABA-receptors and type 2 C protein phosphatases in the appropriate vectors can be used to monitor activation of ABA receptors. These yeast strains therefore create a facile screening system for the identification of cell permeant compounds that act as ABA agonists, i.e. compounds that promote binding of PYR/PYL family members to their protein phosphatase targets. When PYR/PYL proteins are bound to PP2C targets in the yeast two hybrid context, a reporter gene is activated which, depending on strains used, can lead to expression of a reporter construct such as the LacZ/B-galactoisidase marker or to a nutritional reporter gene that enables growth on auxotrophic media.

To conduct these agonist assays, screening compounds are added to microtiter wells and appropriate yeast growth media are added. The wells are then seeded with PYR/PYL-PP2C strains and agonist activity is monitored after growth of the strains on the chemical-containing medium. Numerous approaches can be used to monitor activation including simple growth (via restoration of expression of a nutritional reporter gene) of colorimetric X-gal assays, which are well known in the art. An alternative screening method, called the “Halo Assay,” can also be used to identify agonists. In this assay, yeast strains can be embedded in suitable growth medium containing agarose and chemicals can be spotted onto plates using a pin replicator. The growth medium, lacking a nutrient needed for growth, prevents yeast growth unless one of the screening chemicals supplied enters the yeast cell and activates the PYR/PYL receptors, which results in expression of the nutritional marker genes in the yeast two hybrid strain. Activated cells appear as regions of cell growth and can be easily identified by visual inspection.

Using a combination of the conventional and halo assays as described above, 65,000 screening compounds were tested for activation of PYR1, PYL2, PYL3 or PYL4 expressing yeast two hybrid strains. Hit compounds that activated any of the yeast strains were retested on all 4 yeast strains and activity assessed qualitatively using X-gal staining assays. This led to the identification of the compounds shown in FIG. 8. Estimates of the relative activity of each of these compounds on the PYR/PYL receptors PYR1, PYL1, PYL2, PYL3, and PYL4 is depicted in FIG. 8. We note that the PYL3 yeast strain used in these screening assays is exceptionally sensitive to ABA, and therefore the estimate of the relative activity of ABA or other compounds on the PYL3 receptor may be refined by later performing in vitro phosphatase assays, described below.

As a further validation of hit compounds identified in the yeast two-hybrid assay, we utilized in vitro PP2C assays conducted in the presence of recombinant PYR/PYL receptor proteins PYR1, PYL1, PYL2, or PYL3 and the PP2C HAB1. Recombinant proteins were made as described above in Example 1. Phosphatase assays using the phosphatase substrate pNPP were performed as described in Example 1. As demonstrated by the IC50 values, we found that compound 7653159, which is the same compound as compound 7 in FIG. 8, is a potent agonist of PYR1 and PYL1 inhibition of HAB1 but is not an agonist for PYL2 or PYL3 (FIG. 9). Similarly, compound 6655097, which is the same compound as compound 6 in FIG. 8, is a potent agonist of PYR1 and PYL1 inhibition of HAB1 but is not an agonist for PYL2 or PYL3 (FIG. 9). Compound 7561035, which is the same compound as compound 9 in FIG. 8, is a potent agonist of PYL2 and PYL3 inhibition of HAB1 but is not an agonist for PYR1 or PYL1 (FIG. 9).

Example 3: Phenotypic Analysis of PYR/PYL Overexpression and Loss-of-Function Mutant Plants

Abscisic acid is a multifunctional phytohormone involved in a variety of phyto-protective functions including bud dormancy, seed dormancy and/or maturation, abscission of leaves and fruits, and response to a wide variety of biological stresses (e.g. cold, heat, salinity, and drought). ABA is also responsible for regulating stomatal closure by a mechanism independent of CO₂ concentration. Because PYR/PYL receptor proteins mediate ABA signaling, these phenotypes can be modulated by modulating expression of PYR/PYL. However, as discussed above, experiments with single, triple, and quadruple Pyr/Pyl mutant plants demonstrate that PYL receptors PYL1, 2 and 4 function redundantly with PYR1 in the control of germination and root responses to ABA function. In these experiments, we asked whether other PYR/PYL receptors function redundantly with PYR1 in the control of plant phyto-protective functions such as flowering time, stature, chlorophyll content, and wiltiness. We used the pyr1; pyl1; pyl2; pyl4 quadruple mutants as described above in Example 1 to test the effect of loss of function of multiple PYR/PYL receptors on these phyto-protective functions. We found that pyr1; pyl1; pyl2; pyl4 quadruple mutants exhibit defects in flowering time, stature, and wiltiness (FIG. 10). Relative to a control Arabidopsis plant, pyr1; pyl1; pyl2; pyl4 quadruple mutants flower early, are smaller in stature, and are very wilty. We also examined the effect on phyto-protective functions from overexpressing the PYR/PYL receptor PYL4. We generated transgenic Arabidopsis plants expressing GFP-PYL4 under the control of the high expression promoter Rbcs, and found that plants that overexpress PYL4 exhibit defects in flowering time, stature, wiltiness, and the chlorophyll content of the plants; relative to control plants, these PYL4-overexpressing plants flower later, are darker green, and less wilty (FIG. 10). These results demonstrate that PYR/PYL receptors modulate a wide variety of ABA-mediated activities in plants.

Example 4: Screens of Plant Extracts for PYR/PYL Agonists

The yeast strains expressing PYR/PYL receptors and type 2 C protein phosphatases were also used to screen HPLC-fractionated plant extracts for the presence of endogenous compounds that activate PYL/PYL receptors PYR1, PYL2, PYL3, and/or PYL4. HPLC fractionation of extracts was used to identify compounds different from abscisic acid (the known agonist). This led to the identification of a PYL3/PYL4 selective agonist in extracts made from Hypericum perforatum aerial tissues. Purification of the agonist was achieved via multiple rounds of chromatographic separation coupled to yeast two hybrid assays that informed the fractions to move forward at each step of the purification. The structure of the purified agonist was deduced by X-ray crystallography of crystalline purified agonist. This revealed the compound to be the previously known compound artemisinic acid. This compound has not been reported outside of the genus Artemisia (Asteraceae) and our isolation of this compound from Hypericum (Clusiaceae) suggests the compound may have widespread occurrence in plants, consistent with a functionally important role to plant physiology. Several related compounds were obtained from commercial sources and also found to possess PYL3/PYL4 selective agonist activity (FIG. 12). Following a similar approach to that described above for artemisinic acid, a second naturally occurring ABA agonist was identified from seeds of Cola accumulata and identified by 2D-NMR as a previously undescribed derivative of alpha-copaene, copaenoic acid (FIG. 12).

It is understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and scope of the appended claims. All publications, patents, and patent applications cited herein are hereby incorporated by reference in their entirety for all purposes.

INFORMAL SEQUENCE LISTING SEQ ID NO: 1 xWxxxxxFxxPxxxxxFxxxC SEQ ID NO: 2 Brassica_oleracea {89257688} gb|ABD65175.1| mpsqltpeerselaqsiaefhtyhlgpgscsslhaqrihappeivwsvvrrfdkpqtykhfikscsvedgfemrvgct ravnvisglpantsterldildderrvtgfsiiggehrltnyksvttvhrfekerriwtvvlesyvvdmpegnseddt rmfadtvvklnlqklatvteamarnagdgsgaqvt SEQ ID NO: 3 Brassica_oleracea {89274227} gb|ABD65631.1| mpseltqeerskltqsisefhtyhlgpgscsslhaqrihappeivwsvvrqfdkpqtykhfikscsveegfemrvgct rdvivisglpantsterldmldderrvtgfsiiggehrlknyksyttyhrfererriwtvvlesyvvdmpegnseddt rmfadtvvklnlqklatvteamarnagdgrgsrettcresfhlitafekqrqiteptvyqnppyhtgmtpeprtstvf ieledhrtlpgnltptteehlqrmyqrfwgirqlqrprqsfgerqsi SEQ ID NO: 4 Vitis_vinifera {157341954} emb|CAO63410.1| mqmkylegkqnlmeekgekqcipmdlavreaqfkgslldritwleqrlhklslqletrskqqphpsrmqtagetssrh gpkkelscsfpvfstrnhnhghkqtsqfhvprfeyqeggrenpavvitkltpfhhpkiitilfpisnyfiifffltfd tkkqypllfpilpsrflpishlitqeiekyktsshfsspaslfaamnkaetssmaeaesedsetttptthhltippgl tqpefqelahsisefhtyqvgpgqcssllaqrvhaplptvwsvvrrfdkpqtykhfikschvedgfemrvgclrdvnv isglpaetsterldildderhvtgfsiiggehrlrnyrsvttnhggeiwtvvlesyvvdmpegnteedtrlfadtvvk lnlqklasvtevsqscnypcqfhiienediqpeemnlgvlttsieeqrkkkrvvamkdgstss SEQ ID NO: 5 Vitis_vinifera {147789129} emb|CAN64657.1| maeaesedsetttptthhltippgltqpefqelahsisefhtyqvgpgqcssllaqrvhaplptvwsvvrrfdkpqty khfikschvedgfemrvgclrdvnvisglpaetsterldildderhvtgfsiiggehrlrnyrsvttvheyqnhggei wtvvlesyvvdmpegnteedtrlfadtvvklnlseaxrr SEQ ID NO: 6 Medicago_truncatula {217073334} gb|ACJ85026.1| mekaesstastsdqdsdenhrtqhhltlpsglrqhefdslipfinshhtyligpnqcstllaqrihappqtvwsvvrs fdkpqiykhiikscslkegfqmkvgctrdvnvisglpaatsterldvldderrvtgfsiiggehrlknyrsvtsvhgf gdgdnggeiwtvvlesyvvdvpegnteedtrlfadtvvklnlqklasvtegknrdgdgksh SEQ ID NO: 7 Oryza_sativa_Japonica_Group {115483600} ref|NP_001065470.1| meqqeevppppaglgltaeeyaqvratveahhryavgpgqcssllaqrihappaavwavvrrfdcpqvykhfirscvl rpdphhddngndlrpgrlrevsvisglpaststerldllddahrvfgftitggehrtrnyrsvttvsqldeictlvle syivdvpdgnteddtrlfadtvirlnlqklksyseananaaaaaaappppppaaae SEQ ID NO: 8 Zea_mays {195641068} gb|ACG40002.1| mdqqgaggdaevpaglgltaaeyeqlrstvdahhryavgegqcssllaqrihappeavwavvrrfdcpqvykhfirsc alrpdpeagdalcpgrlrevsvisglpaststerldllddaarvfgfsitggehrlrnyrsvttvselavpaictvvl esyvvdvpdgnteddtrlfadtvirlnlqklksvaeanaaeaaattnsvllprpae SEQ ID NO: 9 Zea_mays {195625286} gb|ACG34473.1| mdqqgaggdaxvpaglgltaaeyeqlrstvdahhryavgegqcssllaqrihappeavwavvrrfdcpqvykhfirsc alrpdpeagdalcpgrlrevsvisglpaststerldllddaarvfgfsitggehrlrnyrsvttvseladpaictvvl esyvvdvpdgnteddtrlfadtvirlnlqklksvteanaaeaaattnsvllprpae SEQ ID NO: 10 Vitis_vinifera {57339249} emb|CAO43790.1| mdphhhhglteeefralepiiqnyhtfepspntctslitqkidapaqvvwpfvrsfenpqkykhfikdctmrgdggvg sirevtvvsglpaststerleilddekhilsfrvvggehrinnyrsvtsvndfskegkdytivlesyivdipegntge dtkmfvdtvvklnlqklavvaitslheneeiadnegpsreislqsetesaergderrdgdgpskacnrnewhcttke SEQ ID NO: 11 Oryza_saliva_Japonica_Group {49388537} dbj|BAD25659.1| mephmeralreavaseaerrelegvvrahhtfpaaeraagpgrrptctslvaqrvdaplaavwpivrgfanpqrykhf ikscelaagdgatvgsvrevavvsglpaststerleildddrhvlsfrvvggdhrlrnyrsvtsvtefsspsspprpy cvvvesyvvdvpegnteedtrmftdtvvklnlqklaavatsssppaagnhh SEQ ID NO: 12 Oryza_sativa_Indica_Group {125538682} gb|EAY85077.1| mephmeralreavaseaerrelegvvrahhtfpaaeraagpgrrptctslvaqrvdaplaavwpivrgfanpqrykhf ikscelaagdgatvgsvrevavvsglpaststerleildddrhvlsfrvvggdhrlrnyrsvtsvtefsspssppspp rpycvvvesyvvdvpegnteedtrmftdtvvklnlqklaavatsssppaagnhh SEQ ID NO: 13 Zea_mays {194695858} gb|ACF82013.1| mpytaprpspqqhsrvlsgggakaashgascaavpaevarhhehaaragqccsavvqaiaapvgavwsvvrrfdrpqa ykhfirscrlvgggdvavgsvrevrvvsglpatssrerleildderrvlsfrvvggehrlanyrsvttvheagagagt gtvvvesyvvdvphgntadetrvfvdtivrcnlqslartaerla SEQ ID NO: 14 Vitis_vinifera {157355387} emb|CAO48777.1| mpsnppksslvvhrinspnsittattasaaannhntstmpphkqvpdavsrhhthvvgpnqccsavvqqiaapvstvw svvrrfdnpqaykhfvkschvvvgdgdygtlrevhvisglpaansterleildderhvlsfsviggdhrlsnyrsvtt lhpspsstgtvvlesyvvdippgntkedtcvfvdtivrcnlqslaqiaenaagckrsss SEQ ID NO: 15 Nicotiana_tabacum {62867576} emb|CA184653.1| mppsspdssvllqrissnttpdfackqsqqlqrrtmpipcttqvpdsvvrfhthpvgpnqccsaviqrisapvstvws vvrrfdnpqaykhfvkschvivgdgdygtlrevrvisglpaassterleildderhvisfsvvggdhrlanyrsvttl hpepsgdgttivvesyvvdvppgntrdetcvfvdtivkcnltslsqiavnvnrrkds SEQ ID NO: 16 Oryza_sativa_Indica_Group {125528236} gb|EAY76350.1| mpyaavrpspppqlsrpigsgagggkacpavpcevaryhehavgagqccstvvqaiaapadavwsvvrrfdrpqaykk fikscrlvdgdggevgsvrevrvvsglpatssrerlevldddrrvlsfrivggehrlanyrsvttvheaaapamavvv esyvvdvppgntweetrvfvdtivrcnlqslartverlapeaprangsidha SEQ ID NO: 17 Oryza_sativa_Japonica_Group {15624049} dbj|BAB68102.1| mpyaavrpspppqlsrpigsgagggkacpavpcevaryhehavgagqcfstvvqaiaapadavwsvvrrfdrpqaykk fikscrlvdgdggevgsvrevrvvsglpatssrerlevldddrrvlsfrivggehrlanyrsvttvheaaapamavvv esyvvdvppgntweetrvfvdtivrcnlqslartverlapeaprangsidha SEQ ID NO: 18 Picea_sitchensis {116783434} gb|ABK22940.1| mdiiagfdqlsfrlsgaskqitktgavqylkgeegygewlkevmgryhyhshdgarecrcssvvvqqveapvsvvwsl vafdqpqvykhfvsncfmrgdlkvgclrevrvvsglpaatsterldildeerhilsfsivggdhrlnnyrsittlhet lingkpgtiviesyvldvphgntkeetclfvdtivkcnlqslahvsnhlnsthrcl SEQ ID NO: 19 Oryza_sativa_Japonica_Group {115468550} ref|NP_001057874.1| meahveralreglteeeraalepavmahhtfppstttattaaatctslvtqrvaapvravwpivrsfgnpqrykhfvr tcalaagdgasvgsvrevtvvsglpaststerlemldddrhiisfrvvggqhrlrnyrsvtsvtefqppaagpgpapp ycvvvesyvvdvpdgntaedtrmftdtvvklnlqmlaavaedsssasrrrd SEQ ID NO: 20 Oryza_sativa_Japonica_Group {115464439} ref|NP_001055819.1| mpytaprpsppqhsriggcggggvlkaagaaghaascvavpaevarhhehaagvgqccsavvqaiaapvdavwsvvrr fdrpqaykhfirscrlldgdgdggavavgsvrevrvvsglpatssrerleildderrvlsfrvvggehrlsnyrsvtt vhetaagaaaavvvesyvvdvphgntadetrmfvdtivrcnlqslartaeqlalaapraa SEQ ID NO: 21 Vitis_vinifera {157351249} emb|CAO41436.1| mpsslqlhrinnidpttvavaataavnchkqsrtplrcatpvpdavasyhahavgphqccsmvvqttaaalptvwsvv rrfdnpqaykhflkschvifgdgdigtlrevhvvsglpaessterleildderhylsfsvvggdhrlcnyrsvttlhp sptgtgtvvvesyvvdippgntkedtcvfvdtivkcnlqslaqmsekltnnnrnss SEQ ID NO: 22 Zea_mays {195617008} gb|ACG30334.1| mpclqasspgsmpyqhhgrgvgcaaeagaavgasagtgtrcgahdgevpaeaarhhehaapgpgrccsavvqrvaapa eavwsvvrrfdqpqaykrfyrscallagdggvgtlrevrvvsglpaassrerlevlddeshvlsfrvvggehrlqnyl svttvhpspaapdaatvvvesyvvdvppgntpedtrvfvdtivkcnlqslattaeklalaav SEQ ID NO: 23 Physcomitrella_patens_subsp._patens {168051209} ref|XP_001778048.1| mqtkgrqadfqtllegqqdlicrfhrhelqphqcgsillqlikapvetvwsvarsfdkpqvykrfiqtceiiegdggv gsirevrlvssipatssierleilddeehiisfrviggghriqnywsvtslhsheidgqmgtivlesyvvdipegntr eethmfvdtvvrcnlkalaqvse SEQ ID NO: 24 Oryza_sativa_Indica_Group {125543492} gb|EAY89631.1| mpcipasspgiphqhqhqhhralagvgmavgcaaeaavaaagvagtrcgahdgevpmevarhhehaepgsgrccsavv qhvaapapavwsvvrrfdqpqaykrfvrscallagdggvgtfrevrvvsglpaassrerleilddeshvlsfrvvgge hriknylsvttyhpspsaptaatvvvesyvvdvppgntpedtrvfvdtivkcnlqslaktaeklaagaraags SEQ ID NO: 25 Oryza_sativa_Japonica_Group {115452475} ref|NP_001049838.1| mpcipasspgiphqhqhqhhralagvgmavgcaaeaavaaagvagtrcgahdgevpmevarhhehaepgsgrccsavv qhvaapaaavwsvvrrfdqpqaykrfvrscallagdggvgtlrevrvvsglpaassrerleilddeshvlsfrvvgge hrlknylsvttvhpspsaptaatvvvesyvvdvppgntpedtrvfvdtivkcnlqslaktaeklaagaraags SEQ ID NO: 26 Medicago_truncatula {217075076} gb|ACJ85898.1| mpspvqfqrfdsntaitngvncpkqiqacryalsslkptvsvpetvvdhhmhvvgqnqcysvviqtinasystvwsvv rrfdypqgykhfvkscnvvasgdgirvgalrevrlvsglpayssterldildeerhvisfsvvggvhrcrnyrsvttl hgdgnggtvviesyvvdvpqgntkeetcsfadtivrcnlqslvqiaekl SEQ ID NO: 27 Zea_mays {195608982} gb|ACG26321.1| mpfaasrtsqqqhsrvatngravavcaghagvpdevarhhehavaagqccaamvqsiaapvdavwslvrrfdqpqryk rfirschlvdgdgaevgsvrelllysglpaessrerleirdderrvisfrvlggdhrlanyrsvttvheaapsqdgrp ltmvvesyvvdvppgntveetrifvdtivrcnlqslegtvirqleiaamphddnqn SEQ ID NO: 28 Zea_mays {194705858} gb|ACF87013.1| mrernssidqehqrgsssrstmpfaasrtsqqqhsrvatngravavcaghagvpdevarhhehavaagqccaamvqsi aapvdavwslvrrfdqpqrykrfirschlvdgdgaevgsvrelllvsglpaessrerleirdderrvisfrvlggdhr lanyrsvttvheaapsqdgrpltmvvesyvvdvppgntveetrifvdtivrcnlqslegtvirqleiaamphddnqn SEQ ID NO: 29 Physcomitrella_patens_subsp._patens {168019160} ref|XP_001762113.1| mmqekqgrpdfqfllegqqdlicrfhkhellphqcgsillqqikapvqtvwlivrrfdepqvykrfiqrcdivegdgv vgsirevqlvssipatssierleilddeehiisfrviggghrlqnywsvtslhrheiqgqmgflylesyvvdipdgnt reethtfvdtvvrcnlkalaqvseqkhllnsnekpaap SEQ ID NO: 30 Vitis_vinifera {157354734} emb|CAO48052.1| mkvyspsqilaergpraqamgnlyhthhllpnqcsslvvqttdaplpqvwsmvrrfdrpqsykrfvrgctlrrgkggv gsvrevnivsglpaeislerldkldddlhvmrftviggdhrlanyhstltlhedeedgvrktvvmesyvvdvpggnsa getcyfantiigfnlkalaavtetmalkanipsgf SEQ ID NO: 31 Physcomitrella_patens_subsp._patens {168030621} ref|XP_001767821.1| mqqvkgrqdfqrlleaqqdlicryhthelkahqcgsillqqikvplpivwaivrsfdkpqvykrfiqtckitegdggy gsirevhlvssvpatcsierleilddekhiisfrvlggghrlqnyssysslheleveghpctlvlesymydipdgntr eethmfvdtvvrcnlkslaqiseqqynkdclqqkqhdqqqmyqqrhpplppipitdknmer SEQ ID NO: 32 Physcomitrella_patens_subsp._patens {168028995} ref|XP_001767012.1| mrfdighndvrgfftceeehayalhsqtvelnqcgsilmqqihapievvwsivrsfgspqiykkfiqaciltvgdggv gsirevflvsgvpatssierleilddekhvfsfrvlkgghrlqnyrsvttlheqevngrqtttvlesyvvdvpdgntr eethmfadtvvmcnlkslaqvaewramqgitqqlstssl SEQ ID NO: 33 Vitis_vinifera {147840019} emb|CAN72620.1| mgnlyhthhllpnqcsslvvqttdaplpqvwsmvrrfdrpqsykrfvrgct/rrgkggygsvrevnivsglpaeisle rldkldddlhvmrftviggdhrlanyhstltlhedeedgvrktvvmesyvvdvpggnsagetcyfantiigfnlkala avtetmalkanipsgf SEQ ID NO: 34 Picea_sitchensis {116785512} gb|ABK23752.1| medlsswregramwlgnppseselvcrhhrhelqgnqcssflvkhirapvhlywsivrtfdqpqkykpfvhscsvrgg itygsirnvnvksglpataseerleilddnehvfsikilggdhrlqnyssiitvhpeiidgrpgtlviesyvvdvpeg ntreetrffvealvkcnlksladvserlasqhhtellert SEQ ID NO: 35 Solanum_tuberosum {78191398} gb|ABB29920.1| mnangfcgvekeyirkhhlhepkenqcssflvkhirapvhlvwslvrrfdqpqkykpfisrcivqgdleigslrevdv ksglpattsterlellddeehilsvrivggdhrlrnyssvisvhpevidgrpgtvvlesfvvdvpegntkdetcyfve alincnlksladiservavqdrtepidqv SEQ ID NO: 36 Medicago_truncatula {217075184} gb|ACJ85952.1| mnngceqqqysvietqyirrhhkhdlrdnqcssalvkhikapvhlvwslvrrfdqpqkykpfisrcimqgdlsigsvr evnvksglpattsterleqlddeehilgirivggdhrlrnyssiitvhpgvidgrpgtmviesfvvdvpegntkdetc yfvealirynlssladvsermavqgrtdpininp SEQ ID NO: 37 Vitis_vinifera {157358179} emb|CAO65816.1| msgygcikmedeyirrhhrheirdnqcssslvkhikapvhlvwslvrsfdqpqkykpfvsrcivqgdleigsvrevnv ksglpattsterlellddeehifgmrivggdhrlknyssivtvhpeiidgrpgtiviesfvvdvpdgntkdetcyfve alikcnlksladvserlaiqdrtepidrm SEQ ID NO: 38 Vitis_vinifera {157360187} emb|CAO69376.1| mngnglssmeseyirrhhrhepaenqcssalvkhikapvplvwslvrrfdqpqkykpfisrcvvqgnleigslrevdv ksglpattsterlelldddehilsmriiggdhrlrnyssiislhpeiidgrpgtmviesyvvdvpegntkdetcyfve alikcnlksladvserlavqdrtepidrm SEQ ID NO: 39 Oryza_sativa_Japonica_Group {125597584} gb|EAZ37364.1| meahveralreglteeeraalepavmahhtfppstttattaaatctslvtqrvaapvravwpivrsfgnpqrykhfvr tcalaagngpsfgsvrevtvvsgpsrlppgterlemldddrhiisfrvvggqhrlrnyrsvtsvtefqppaagpgpap pycvvvesyvvdvpdgntaedtrmftdtvvklnlqmlaavaedsssasrrrd SEQ ID NO: 40 Capsicum_annuum {47558817} gb|AAT35532.1| mmnangfsgvekeyirkhhlhqpkenqcssflvkhirapvhlvwslvrrfdqpqkykpfvsrciaqgdleigslrevd vksglpattsterlellddeehilsfriiggdhrlrnyssiislhpevidgrpgtlviesfvvdvpqgntkdetcyfv ealincnlksladvserlavqdrtepidqv SEQ ID NO: 41 Populus_trichocarpa {118481075} gb|ABK92491.1| mngsdaysateaqyvrrhhkheprenqctsalvkhikapahlvwslvrrfdqpqrykpfvsrcvmngelgigsvrevn vksglpattsterlellddeehilgvqivggdhrlknyssimtvhpefidgrpgtlviesfivdvpdgntkdetcyfv ealircnlksladvsermavqdrvepvnqf SEQ ID NO: 42 Capsicum_annuum {104304209} gb|ABF72432.1| mnangfsgvekeyirkhhlhqpkenqcssflvkhirapvhlvwslvrrfdqpqkykpfvsrciaqgdleigslrevdv ksglpattsterlellddeehilsfriiggdhrlrnyssiislhpevidgrpgtlviesfvvdvpqgntkdetcyfve alincnlksladvserlavqdrtepidqv SEQ ID NO: 43 Populus_trichocarpa_x_Populus_deltoides {118489403} gb|ABK96505.1| mngsdaysateaqyvrrhhkheprenqctsalvkhikapahlvwslvrrfdqpqrykpfvsrcvmngelgigsvrevn vksglpattsterlellddeehilgvqivggdhrlknyssimtvhpefidgrpgtlviesfivdvpdgntkdetcyfv kalircnlksladvsermavqdrvepvnqf SEQ ID NO: 44 Pisum_sativum {56384584} gb|AAV85853.1| mnnggeqysaietqyirrrhkhdlrdnqcssalvkhikapvhlvwslvrrfdqpqkykpfvsrcimqgdlgigsvrev nvksglpattsterleqlddeehilgirivggdhrtrnyssvitvhpevidgrpgtmviesfvvdvpegntrdetcyf vealirgnissladvsermavqgrtdpinvnp SEQ ID NO: 45 Vitis_vinifera {157349888} emb|CAO39744.1| meaqvicrhhaheprenqcssvlvrhvkapanlvwslvrrfdqpqkykpfvsrcvvqgdlrigsvrevnvktglpatt sterlelfdddehvlgikildgdhrlrnyssvitvhpeiidgrpgtlviesfvvdvpegntkddtcyfvralincnlk claevsermamlgrvepanav SEQ ID NO: 46 Vitis_vinifera {147856414} emb|CAN82501.1| mmeaqvicrhhaheprenqcssvlvrhvkapanlvwslvrrfdqpqkykpfvsrcvvqgdlrigsvrevnvktglpat tsterlelfdddehvlgikildgdhrlrnyssvitvhpeiidgrpgtiviesfvvdvpegntkddtcyfvralincnl kclaevsermamlgrvepanav SEQ ID NO: 47 Arachis_hypogaea {196196276} gb|ACG76109.1| mmngscggggggeaygaieaqyirrhhrheprdnqctsalvkhirapvhlvwslvrrfdqpqkykpfvsrcimqgdlg igsvrevnvksglpattsterleqlddeehilgirivggdhrtrnyssiitvhpeviegrpgtmviesfvvdvpdgnt kdetcxfvealircnlssladvsermavqgrtdpinq SEQ ID NO: 48 Zea_mays {195639836} gb|ACG39386.1| mvvemdggvgvaagggggaqtpapapprrwrladercdlrametdyvrrfhrheprdhqcssavakhikapvhlvwsl vrrfdqpqlfkpfvsrcemkgnieigsvrevnyksglpatrsterlellddderilsvrfvggdhrlqnyssiltvhp evidgrpgtiviesfvvdvpdgntkdetcyfveallkcnlrslaevsegqvimdqtepldr SEQ ID NO: 49 Zea_mays {194691986} gb|ACF80077.1| mvvemdggvgvaaaggggaqtpapppprrwrladercdlrametdyvrrfhrheprdhqcssavakhikapvhlvwsl vrrfdqpqlfkpfvsrcemkgnieigsvrevnvksglpatrsterlellddderilsvrfvggdhrlqnyssiltvhp evidgrpgtiviesfvvdvpdgntkdetcyfveallkcnlrslaevsegqvimdqtepldr SEQ ID NO: 50 Oryza_sativa_Japonica_Group {115468346} ref|NP_001057772.1| mngvggaggaaagklpmvshrrvqwrladercelreeemeyirrfhrhepssnqctsfaakhikaplhtvwslvrrfd qpqlfkpfvrncvmreniiatgcirevnvqsglpatrsterlellddnehilkvnfiggdhmlknyssiltvhsevid gqlgtlvvesfivdvpegntkddisyfienvlrcnlrtladvseerlanp SEQ ID NO: 51 Oryza_sativa_Indica_Group {125555582} gb|EAZ01188.1| mngaggaggaaagklpmvshrqvqwrladercelreeemeyirqfhrhepssnqctsfvakhikaplqtvwslvrrfd qpqlfkpfvrkcvmreniiatgcvrevnvqsglpatrsterlellddnehilkvkfiggdhmlknyssiltihsevid gqlgtivvesfvvdipegntkddicyfienilrcnlmtladvseerlanp SEQ ID NO: 52 Oryza_sativa_Japonica_Group {125581525} gb|EAZ22456.1| mvevgggaaeaaagrrwrladercdlraaeteyvrrfhrheprdhqcssavakhikapvhlvwslvrrfdqpqlfkpf vsrcemkgnieigsvrevnvksglpatrsterlellddnehilsvrfvggdhrlknyssiltvhpevidgrpgtivie sfvvdvpegntkdetcyfveallkcnlkslaevserlvcqgpnrapstr SEQ ID NO: 53 Oryza_sativa_Japonica_Group {115445369} ref|NP_001046464.1| mvevgggaaeaaagrrwrladercdlraaeteyvrrfhrheprdhqcssavakhikapvhlvwslvrrfdqpqlfkpf vsrcemkgnieigsvrevnvksglpatrsterlellddnehilsvrfvggdhrlknyssiltvhpevidgrpgtlvie sfvvdvpegntkdetcyfveallkcnlkslaevserlvvkdqtepldr SEQ ID NO: 54 Medicago_truncatula {217075288} gb|ACJ86004.1| mekmngtenngvfnstemeyirrhhnqqpgenqcssalvkhirapvplvwslvrrfdqpqkykpfvsrcvvrgnleig slrevdvksglpattsterlevlddnehilsiriiggdhrlrnyssimslhpeiidgrpgtiviesfvvdvpegntkd etcyfvealikcnlkslsdvseghavqdltepldrvhellisg SEQ ID NO: 55 Medicago_truncatula {217071196} gb|ACJ83958.1| mekmngtenngvfnstemeyirrhhnqqpgenqcssalvkhirapvplvwslvrrfdqpqkykpfvsrcvvrgnleig slrevdvksglpattsterlevlddnehilsiriiggdhrlrnyssimslhpeiidgrpgtiviesfvvdvpegntkd etcyfvealikcnlkslsdvseghaaqdltepldrmhellisg SEQ ID NO: 56 Zea_mays {195625792} gb|ACG34726.1| mvglvggstaraehvvanaggeaeyvrrmhrhaptehqctstivkhikapvhlvwqlvrrfdqpqrykpfvrncvvrg dqlevgslrdvnvktglpattsterleqldddlhilgvkfvggdhrlqnyssiitvhpesidgrpgtiviesfvvdvp dgntkdetcyfveavikcnlnslaevseqlavesptslidq SEQ ID NO: 57 Zea_mays {195608384} gb|ACG26022.1| mvglvggstaraehvvanaggeaeyvrrmhrhaptehqctstivkhikapvhlvwelvrrfdqpqrykpfvrncvvrg dqlevgslrdvnyktglpattsterleqldddlhilgvkfvggdhrlqnyssiitvhpesidgrpgtiviesfvvdvp dgntkdetcyfveavikcnlnslaevseqlavesptslidq SEQ ID NO: 58 Zea_mays {194704156} gb|ACF86162.1| mvmvemdggvgggggggqtpaprrwrladercdlrametdyvrrfhrheprehqcssavakhikapvhlvwslvrrfd qpqlfkpfvsrcemkgnieigsvrevnvksglpatrsterlellddnehilsvrfvggdhrlqnyssiltvhpevidg rpgtiviesfvvdvpdgntkdetcyfveallkcnlkslaevserqvvkdqtepldr SEQ ID NO: 59 Oryza_sativa_Japonica_Group {115468344} ref|NP_001057771.1| mngaggaggaaagklpmvshrrvqcrladkrcelreeemeyirqfhrhepssnqctsfvakhikaplqtvwslvrrfd qpqlfkpfvrkcvmreniivtgcvrevnvqsglpatrsterlellddnehilkvkfiggdhmlknyssiltihsevid gqlgtivvesfvvdipdgntkddicyfienvlrcnlmtladvseerlanp SEQ ID NO: 60 Zea_mays {194701978} gb|ACF85073.1| mvglvggstaraehvvanaggeteyvrrlhrhapaehqctstlvkhikapvhlvwelvrsfdqpqrykpfvrncvvrg dqlevgslrdvnvktglpattsterleqldddlhilgvkfvggdhrlqnyssiitvhpesidgrpgtiviesfvvdvp dgntkdetcyfveavikcnlkslaevseqlavesptspidq SEQ ID NO: 61 Oryza_sativa_Indica_Group {125555585} gb|EAZ01191.1| mngvggaggaaagklpmvshrrvqwrladercelreeemeyirrfhrhepssnqctsfaakhikaplhtvwslvrrfd qpqlfkpfvrncvmreniiatgcirevnvqsglpatrsterlellddnehilkvkfiggdhmlknyssilivhsevid gqlgtivvesfivdvlegntkddisyfienvlrcnlrtladvseerlanp SEQ ID NO: 62 Oryza_sativa_Japonica_Group {115462647} ref|NP_001054923.1| mvglvggggwrvgddaaggggggavaagaaaaaeaehmrrlhshapgehqcssalvkhikapvhlvwslvrsfdqpqr ykpfvsrcvvrggdleigsvrevnvktglpattsterlelldddehilsvkfvggdhrlrnyssivtvhpesidgrpg tlviesfvvdvpdgntkdetcyfveavikcnltslaevserlavqsptspleq SEQ ID NO: 63 Oryza_sativa_Japonica_Group {50251668} dbj|BAD29692.1| mvemdaggrpepsppsgqcssavtmrinapvhlvwsivrrfeephifqpfvrgctmrgstslavgcvrevdfksgfpa kssverleilddkehvfgvriiggdhrlknyssvltakpevidgepatlvsesfvvdvpegntadetrhfveflircn lrslamvsqrlllaqgdlaeppaq SEQ ID NO: 64 Vitis_vinifera {147797548} emb|CAN64668.1| mngnglssmeseyirrhhrhepaenqcssalvkhikapvplvwslvrrfdqpqkykpfisrcvvqgnleigslrevdv ksglpattsterlelldddehilsmriiggdhrlrnyssiislhpeiidgrpgtmviesyvvdvpegntkdetcyfsl advserlavagtvtepidrm SEQ ID NO: 65 Oryza_sativa_Indica_Group {218190432} gb|EEC72859.1| mvemdaggrpepsppsgqcssavtmrinapvhlvwsivrrfeephifqpfvrgctmrgstslavgcvrevdfksgfsa kssverleilddkehvfgvriiggdhrlknyssvltakpevidgepatlvsesfvidvpegntadetrhfveflircn lrslamvsqrlllaqgdlaeppaq SEQ ID NO: 66 Oryza_sativa_Japonica_Group {125585934} gb|EAZ26598.1| mpcipasspgiphqhqhqhhralagvgmavgcaaeaavaaagvagtrcgahdgevpmevarhhehaepgsgrccsavv qhvaapaaavwsvvrrfdqpqaykrfvrscallagdgglgkvrerleilddeshvlsfrvvggehrlknylsvttvhp spsaptaatvvvesyvvdvppgntpedtrvfvdtivkcnlqslaktaeklaagaraags SEQ ID NO: 67 Rheum_australe {197312913} gb|ACH63237.1| mngdgyggseeefvkryhehvladhqcssvlvehinaplhlvwslvrsfdqpqkykpfvsrcvvqggdleigsvrevd vksglpattsmeelellddkehvirvkfvggdhrlknyssivslhpeiiggrsgtmviesfivdiadgntkeetcyfi eslincnlkslscvserlavediaeriaqm SEQ ID NO: 68 Oryza_sativa_Japonica_Group {125593228} gb|EAZ33287.1| mvglvggggwrvgddaaggggggavaagaaaaaeaehmrrlhsqgprrapvqlrarqahqgscsppriecanfavfla ardpkivwslvrsfdqpqrykpfvsrcvvrggdleigsvrevnyktglpattsterlelldddehilsvkfvggdhrl rnyssivtvhpesidgrpgtlviesfvvdvpdgntkdetcyfveavikcnltslaemvrmislvlpfmlvdrmsgitc eshlettivrcgeyavlahv SEQ ID NO: 69 Oryza_sativa_Japonica_Group {125581370} gb|EAZ22301.1| mephmeralreavaseaerrelegvvrahhtgwnaplaavwphrarvrptrsgtstsssrassppgdgatvgsvreva vvsglpaststerleildddrhvlsfrvvggdhrlrnyrsvtsvtefsspsspprpycvvvesyvvdvpegnteedtr mftdtvvklnlqklaavatsssppaagnhh SEQ ID NO: 70 Oryza_sativa_Japonica_Group {125581524} gb|EAZ22455.1| mevvwsivrrfeephifqpfvrgctmrgstslavgcvrevdfksgfpakssverleilddkehvfgvriiggdhrlkn yssvltakpevidgepatlvsesfvvdvpegntadetrhfveflircnirslamvsqrlllaqgdlaeppgq SEQ ID NO: 71 Oryza_sativa_Japonica_Group {125594587} gb|EAZ34646.1| mpytaprpsppqhsriggcggggvlkaagaaghaascvavpaevarhhehaagvgqccsavvqaiaapvdavwrtsts sgaaaswtatatagplpvgsvrefrvlsglpgtssrerleildderrvlsfrvvggehrlsnyrsvttvhetaagaaa avvvesyvvdvphgntadetrmfvdtivrcnlqslartaeqlalaapraa SEQ ID NO: 72 Vitis_vinifera {147770961} emb|CAN76441.1| mpisslpfslytvtpnplklitthahaftphthiftlkfmshtycphihhitsihythllxpiphmplqpplpphpil psmpafqhlystnqhlqvalfsargpnirdfnfqdadllkldilapgsliwaawspngtdeanyvgegsptvamiakr gprhgkymafcxmyrdnvapkgvnxavatvktkrtiqlktsleiachyaginisgingevmpgqweyqvgpgqcssll aqrvhvplsavgsvvhrfdkpqryqhvikscriedgfemrmgxlrdvniisglptatntgrldmqdderhvtrcphqr qseskytennnsdassikspingpsehlktaaspktesiividtskflneedfegkdetsssnqvqiedenwetrfpn tdagiw SEQ ID NO: 73 Vitis_vinifera {147828564} emb|CAN59881.1| mpsaxksstvplslxqfklglrhghrvipwgdldslamlqrqldvdilvtghthrftaykheggvvinpgsatgafgs itydvnpsfvlmdidglrvvvcvyelidetaniikelharkisfgtksmixclllkrrstpkfrrkklflfqcrvqmt ltltnlavsgiaqtlqvdqwtvcalifmtrrdihldkarfldfkdmgklladasglrkalsggxvtagmaifdtmrhi rpdvptvcvglaavamiakrgprhgkymafcpmyrdnvapkgvnvavvtvktkrtiqlktsleiachyaginisging evmpgqweyqvgpgqcssllaqrvhvplsavgsvvhrfdkpqryqhvikscriedgfemrmgrlrdvniisglptatn tgrldmqddexhvtrcphqrqseskytennnsdassvkspingpsehlktaax SEQ ID NO: 74 Oryza_sativa_Indica_Group {149392053} gb|ABR25904.1| eigsvrevnyktglpattsterlelldddehilsvkfvggdhrlrnyssivtvhpesidgrpgtlviesfvvdvpdgn tkdetcyfveavikcnl SEQ ID NO: 75 Zea_mays {194701080} gb|ACF84624.1| mvvemdggvgvaaaggggaqtpapppprrwrladercdlrametdyvrrfhrheprdhqcssavakhikapvhlvwsl vrrfdqpqlfkpfvsrcemkgnieigsvrevnvksglpatrsterlellddderilsvrfvggdhrlqvcsvlhlsif caaharyfahhlkcvleflcqmhldvlpcddaile SEQ ID NO: 76 Oryza_sativa_Japonica_Group {125597418} gb|EAZ37198.1| mngctggaggvaagrlpavslqqaqwklvdercelreeemeyvrrfhrheigsnqcnsfiakhvraplqnvwslvrrf dqpqtykpfvrkcvmrgnvetgsvreiivqsglpatrsierleflddneyilrvkfiggdhmlkkripkktyaissrt csdsaiiavgqsncapeitamnggvsiqpwlillaffsspsnqtnpdslrdmhpgswfqillvlamftcskgsvlpps ekvnv SEQ ID NO: 91 GxxRxVxxxSGxPAxxSxExLxxxDxxxxxxxxxxxGGxHRLxNYKSxxx SEQ ID NO: 92 xxxxxxxxxESxxVDxPxGNxxxxTxxFxxxxxxxNLxxLx SEQ ID NO: 93 CxSxxxxxxxAPxxxxWxxxxxFxxPxxxxxFxxxC SEQ ID NO: 94 GxxRxVxxxSxxPAxxSxExLxxxD SEQ ID NO: 95 GGxHRLxNYxS SEQ ID NO: 96 CxSxxxxxxxAPxxxxWxxxxxFxxPxxxKxFxxxC SEQ ID NO: 97 GxxRxVxxxSxLPAxxSxExLxxxD SEQ ID NO: 98 GGxHRLxNYxS SEQ ID NO: 99 ESxxVDxPxGNxxxxTxxFxxxxxxxNLxxL SEQ ID NO: 100 HxxxxxxxxCxSxxxxxxxAPxxxxWxxxxxFxxPxxYKxFxxxC SEQ ID NO: 101 VGRxVxVxSGLPAxxSxExLxxxDxxxxxxxFxxxGGxHRLxNYxSVT SEQ ID NO: 102 VxESYxVDxPxGNxxxxTxxFxDxxxxxNLQxL SEQ ID NO: 103 HxHxxxxxQCxSxLVKxIxAPxHxVWSxVRRFDxPQKYKPFxSRCxVxGx SEQ ID NO: 104 ExGxxREVxxKSGLPATxSTExLExLDDxEHILxIxIxGGDHRLKNYSSxxxxHxExIxGxxGTx SEQ ID NO: 105 xxESFVVDVPxGNTKxxTCxFVExLIxCNLxSLAxxxERL SEQ ID NO: 106 CxSxxVxTIxAPLxLVWSILRxFDxPxxxxxFVKxCxxxSGxGG SEQ ID NO: 107 GSVRxVTxVSxxPAxFSxERLxELDDESHVMxxSIIGGxHRLVNYxSKT SEQ ID NO: 108 MEPHMESALRQGLSEAEQRELEGVVRAHHTFPGRAPGTCTSLVTQRVDAPLAAVWPI VRGFGSPQRYKHFIKSCDLKAGDGATVGSVREVTVVSGLPASTSTERLEILDDHRHILS FRVVGGDHRLRNYRSVTSVTEFQPGPYCVVLESYVVDVPDGNTEEDTRMFTDTVVKL NLQKLAAIATSSSAN SEQ ID NO: 109 MDQQGAGGDVEVPAGLGLTAAEYEQLRPTVDAHHRYAVGEGQCSSLLAQRIHAPPA AVWAIVRRFDCPQVYKHFIRSCAVRPDPDAGDALRPGRLREVCVISGLPASTSTERLDH LDDAARVFGFSITGGEHRLRNYRSVTTVSELAGPGICTVVLESYAVDVPDGNTEDDTR LFADTVIRLNLQKLKSVAEASTSSSAPPPPSE SEQ ID NO: 110 MPCIQASSPGGMPHQHGRGRVLGGGVGCAAEVAAAVAASAGGMRCGAHDGEVPAE AARHHEHAAAGPGRCCSAVVQHVAAPAAAVWSVVRRFDQPQVYKRFVRSCALLAG DGGVGTLREVRVVSGLPAASSRERLEVLDDESHVLSFRVVGGEHRLRNYLSVTTVHPS PAAPDAATVVVESYVVDVPPGNTPEDTRVFVDTIVKCNLQSLATTAEKLAAV SEQ ID NO: 111 MEKAESSASTSEPDSDENHHRHPTNHHINPPSGLTPLEFASLIPSVAEHHSYLVGSGQCS SLLAQRVQAPPDAVWSVVRRFDKPQTYKHFIKSCAVKEPFHMAVGVTRDVNVISGLP AATSTERLDLLDDIRCVTGFSIIGGEHRLRNYRSVTTVHSFEDDADDGKIYTVVLESYV VDVPDGNTEEDTRLFADTVVKLNLQKLASVTEGTNRDGDGKSHSR SEQ ID NO: 112 MEKTHSSSAEEQDPTRRHLDPPPGLTAEEFEDLKPSVLEHHTYSVTPTRQSSSLLAQRIH APPHAVWSVVRCFDNPQAYKHFIKSCHVKEGFQLAVGSTRDVHVISGLPAATSTERLD LLDDDRHVIGFTIVGGDHRLRNYRSVTSVHGFECDGKIWTVVLESYVVDVPEGNTEED TRLFADTVVKLNLQKLASVSEGMCGDGDGDGDGKGNKS SEQ ID NO: 113 MLQNSSMSSLLLHRINGGGGATTATNCHDTVFMTVPDGVARYHTHAVAPNQCCSSVA QEIGASVATVWSVLRRFDNPQAYKHFVKSCHVIGGDGDVGTLREVHVISGLPAARSTE RLEILDDERHVISFSVVGGDHRLANYRSVTTLHPTASSASGGCSGTVVVESYVVDVPPG NTREDTRVFVDTIVKCNLQSLAQTAENLTLRKNNNNDYKCCS SEQ ID NO: 114 MTSLQFHRFNPATDTSTAIANGVNCPKPPSTLRLLAKVSLSVPETVARHHAHPVGPNQ CCSVVIQAIDAPVSAVWPVVRRFDNPQAYKHFVKSCHVVAAAGGGEDGIRVGALREV RVVSGLPAVSSTERLEILDDERHVMSFSVVGGDHRLRNYRSVTTLHGDGNGGTVVIES YVVDVPPGNTKEETCVFVDTIVRCNLQSLAQIAET SEQ ID NO: 115 AYPVLGLTPEEFSELESIINTHHKFEPSPEICSSIIAQRIDAPAHTVWPLVRSFENPQKYKH FVKSCNMRSGDGGVGSIREVTVVSGLPASTSTERLEILDDDKHLLSFRVVGGEHRLHN YRSVTSVNEFKNPDNGKVYTIVLESYVVDIPEGNTGVDTKMFVDTVVKLNLQKLGE SEQ ID NO: 116 EFTELESTINTHHKFEASPEICSSIIAQRIDAPAHTVWPLVRSFENPQKYKHFVKSCNMRS GDGGVGSIREVTVVSGLPASTSTERLEILDDDNHLLSFRVVGGEHRLHNYRSVTSVNEF KRPDNGKVYTIVLESYVVDIPEGNTGVDTKMFVDTVVKLNLQKLGEVAMATN SEQ ID NO: 117 MTELSSREVEYIRRHHSKAAEDNQCASALVKHIRAPLPLVWSLVRRFDEPQKYKPFVS RCVVRGNLEIGSLREVDVKSGLPATTSTERLEILDDNHHILSVRIIGGDHRLRNYSSIMS LHPEIVDGRPGTLVIESFVVDIPEGNTKDETCYFVEALIKCNLKSLADVSEGLTLQDHTE PIDRKYELLITRG SEQ ID NO: 118 MNGGESYGAIETQYIRRHHKHEPRENQCTSALVKHIRAPVHLVWSLVRRFDQPQKYKP FVSRCIMQGDLGIGSVREVNVKSGLPATTSTERLEQLDDEEHILGIRIVGGDHRLRNYSS IITVHPEVIDGRPGTMVIESFVVDVPDGNTRDETCYFVEALIRCNLSSLADVSERMAVQ GRTNPINH SEQ ID NO: 119 MSPNNPSTIVSDAVARHHTHVVSPHQCCSAVVQEIAAPVSTVWSVVRRFDNPQAYKH FVKSCHVILGDGDVGTLREVRVISGLPAAVSTERLDVLDDERHVIGFSMVGGDHRLSN YRSVTILHPRSATDTVVVESYVVDVPAGNTTEDTRVFVDTILRCNLQSLAKFAENLTN KLHQR SEQ ID NO: 120 MSRSHNKRKPFSFIFKITLLELLSSLLSSSLRFAMDKTHSGEEQDPNPTHPTRNHLDPPPG LTPEEFEDLKPSVLEHHTYSVTPTRQCSSLLAQRIHAPPHTVWTVVRCFDNPQAYKHFI KSCHVKEGFQLAVGSTRDVHVISGLPAATSTERLDLLDDDRHVIGFTIVGGDHRLRNY RSVTSVHGFERDGKIWTVVLESYVVDVPEGNTEEDTRLFADTVVKLNLQKLASVTEG MCGDSDGKGNN SEQ ID NO: 121 MEKAESSASTSEPDSDDNHHRHPTNHHLNPPSGLTPLEFASLVPSVAEHHSYLVGPGQC SSLLAQRVHAPPDAVWSFVRRFDKPQTYKHFIKSCAVKEPFHMAVGVTRDVNVISGLP AATSTERLDFLDDVRRVTGFSIIGGEHRLRNYRSVTTVHSFDDDNASADGKIYTVVLES YVVDVPDGNTEEDTRLFADTVVKLNLQKLASVTEGTNGDGDGKPHSR SEQ ID NO: 122 MPSSLHFDRFNPITHAATTVAIANGVNCPKQPQAPPSSTAARRLVVPSLSSGRGIAAPDT VALHHAHVVDPNQCCSIVTQHINAPVSAVWAVVRRFDNPQGYKNFVRSCHVITGDGI RVGAVREVRVVSGLPAETSTERLEILDDERHVISFSMVGGDHRLRNYQSVTTLHANGN GTLVIESYVVDVPQGNTKEETCVFVDTIVRCNLQSLAQIAENRTNNCEHTAQHC SEQ ID NO: 123 MNGIGNDGGGGLSNVEMEYIRRHHRHEPGENQCGSALVKHIRAPVPQVWSLVRRFDQ PQKYKPFVSRCVVRGNLEIGSLREVDVKSGLPATTSTERLELLDDNEHLLSIRIIGGDHR LRNYSSIMSLHPEIIDGRPGTLVIESFVVDVPEGNTKDETCYFVEALIKCNLKSLADVSE GIAVQDRTEPIDRI SEQ ID NO: 124 MVARHHAHAVGPNQCCSFVIQAIDAPVSAVWPVVRRFDNPQAYKHFVKSCHVVAAG GAGGDGGIHVGALREVRVVSGLPAVSSTERLEILDDERHVMSFSVVGGDHRLRNYRS VTTLHGDGSNGGTVVIESYVVDIPAGNTKEETCVFVDTIVRCNLQSLAQMAENMGS SEQ ID NO: 125 MTILPHSNNKSSNHKFIAHQNYMASETHHHVQGLTPEELTKLEPIIKKYHLFEQSPNTCF SIITYRIEAPAKAVWPFVRSFDNPQKYKHFIKGCNMRGDGGVGSIREVTVVSGLPASTS TERLEILDDDKHVLSFRVVGGEHRLKNYRSVTSVNEFNKEGKVYTIVLESYIVDIPEGN TEEDTKMFVDTVVKLNLQKLGVVAMASSMHGQ SEQ ID NO: 126 MNRIGNGGGGGGGLSNVEMEYIRRHHRHEPGENQCGSALVKHIRAPVPQVWSLVRRF DQPQKYKPFISRCVVRGNLEIGSLREVDVKSGLPATTSTERLELLDDNEHILSIRIIGGDH RLRNYSSIMSLHPEIIDGRPGTLVIESFVVDVPEGNTKDETCYFVEALIKCNLKSLADVS EGLAVQDCTEPIDRI SEQ ID NO: 127 MASETHHHVQGLTPEELTQLEPIIKKYHLFEASSNKCFSIITHRIEAPASSVWPLVRNFD NPQKYKHFIKGCNMKGDGSVGSIREVTVVSGLPASTSTERLEILDDDKHVLSFRVVGG EHRLQNYRSVTSVNEFHKEGKVYTIVLESYIVDIPEGNTEEDTKMFVDTVVKLNLQKL GVVAMASSMNGR SEQ ID NO: 128 MLPNNPSTIVPDAVARHHTHVVSPQQCCSAVVQEIAAPVSTVWSVVRRFDNPQAYKH FVKSCHVILGDGDVGTLREVHVISGLPAAVSTERLDVLDDERHVIGFSMVGGDHRLFN YRSVTTLHPRSAAGTVVVESYVVDVPPGNTTEDTRVFVDTILRCNLQSLAKFAENLTK LHQR SEQ ID NO: 129 MNGGESYGAIETQYIRRHHKHEPRENQCTSALVKHIRAPVHLVWSLVRRFDQPQKYKP FVSRCIMQGDLGIGSVREVNVKSGLPATTSTERLEQLDDEEHILGIRIVGGDHRLRNYSS IITVHPEVIDGRPGTMVIESFVVDVPDGNTRDETCYFVEALIRCNLSSLADVSERMAVQ GRTNPINH SEQ ID NO: 130 MGITIGIQCLEIEEISICDGMFCYLVDFVDVKEKMNYCLMWFGYFPSQVWSLVRRFDQP QKYKPFVSRCIMQGDLGIGSVREVNVKSGLPATTSTERLEQLDDEEHILGIRIVGGDHR LRNYSSIITVHPEVIDGRPSTMVIESFVVDVPDGNTRDETCYFVEALIRCNLSSLADVSE RMAVQGRTDPINH SEQ ID NO: 131 MNGGESYGAIETQYIRRHHKHEPRENQCTSALVKHIRAPVHLVWSLVRRFDQPQKYKP FVSRCIMQGDLGIGSVREVNVKSGLPATTSTERLEQLDDEEHILGIRIVGGDHRLRNYSS IITVHPEVIDGRPSTMVIESFVVDVPDGNTRDETCYFVEALIRCNLSSLADVSERMAVQG RTDPINH SEQ ID NO: 132 METHVERALRATLTEAEVRALEPAVREHHTFPAGRVAAGTTTPTPTTCTSLVAQRVSA PVRAVWPIVRSFGNPQRYKHFVRTCALAAGDGASVGSVREVTVVSGLPASSSTERLEV LDDDRHILSFRVVGGDHRLRNYRSVTSVTEFQPGPYCVVVESYAVDVPEGNTAEDTR MFTDTVVRLNLQKLAAVAEESAAAAAAGNRR SEQ ID NO: 133 MEPHMETALRQGGLSELEQRELEPVVRAHHTFPGRSPGTTCTSLVTQRVDAPLSAVWP IVRGFAAPQRYKHFIKSCDLRSGDGATVGSVREVTVVSGLPASTSTERLEILDDDRHILS FRVVGGDHRLRNYRSVTSVTEFHHHHQAAAGRPYCVVVESYVVDVPEGNTEEDTRM FTDTVVKLNLQKLAAIATSSAAAAASNSST SEQ ID NO: 134 MVESPNPNSPSRPLCIKYTRAPARHFSPPLPFSSLIISANPIEPKAMDKQGAGGDVEVPA GLGLTAAEYEQLRSTVDAHHRYAVGEGQCSSLLAQRIQAPPAAVWAIVRRFDCPQVY KHFIRSCALRPDPEAGDALRPGRLREVSVISGLPASTSTERLDLLDDAARVFGFSITGGE HRLRNYRSVTTVSELADPGICTVVLESYVVDVPDGNTEDDTRLFADTVIRLNLQKLKS VAEANAAAAASFVSVVPPPEPEE SEQ ID NO: 135 MPCLQASSSPGSMPHQHHGRVLAGVGCAAEVAAAAVAATSPAAGMRCGAHDGEVP AEAARHHEHAAPGPGRCCSAVVQHVAAPASAVWSVVRRFDQPQAYKRFVRSCALLA GDGGVGTLREVRVVSGLPAASSRERLEVLDDESHVLSFRVVGGEHRLQNYLSVTTVHP SPAAPDAATVVVESYVVDVPPGNTPEDTRVFVDTIVKCNLQSLATTAEKLAAV SEQ ID NO: 136 MVEMDGGVGVVGGGQQTPAPRRWRLADELRCDLRAMETDYVRRFHRHEPRDHQCS SAVAKHIKAPVHLVWSLVRRFDQPQLFKPFVSRCEMKGNIEIGSVREVNVKSGLPATR STERLELLDDNEHILSVKFVGGDHRLQNYSSILTVHPEVIDGRPGTLVIESFVVDVPDGN TKDETCYFVEALLKCNLKSLAEVSERQVIKDQTEPLDR SEQ ID NO: 137 MPYTAPRPSPQQHSRVTGGGAKAAIVAASHGASCAAVPAEVARHHEHAARAGQCCS AVVQAIAAPVGAVWSVVRRFDRPQAYKHFIRSCRLVDDGGGGAGAGAGATVAVGSV REVRVVSGLPATSSRERLEILDDERRVLSFRVVGGEHRLANYRSVTTVHEAEAGAGGT VVVESYVVDVPPGNTADETRVFVDTIVRCNLQSLARTAERLALALA SEQ ID NO: 138 EXLXXXDXXXXXXXXXXXGGXHXL 

What is claimed is:
 1. An expression cassette comprising a heterologous promoter operably linked to a polynucleotide encoding a mutated PYR/PYL receptor polypeptide, wherein the mutated PYR/PYL receptor polypeptide is at least 90% identical to any of SEQ ID NO:85, SEQ ID NO:87, SEQ ID NO:88, SEQ ID NO:89, or SEQ ID NO:90, and further comprises an amino acid substitution, relative to a naturally-occurring PYR/PYL receptor polypeptide, at position H60 as numbered with reference to SEQ ID NO:89, wherein the naturally-occurring PYR/PYL receptor polypeptide does not inhibit a type 2 protein phosphatase (PP2C) in the absence of abscisic acid (ABA) and wherein the mutated PYR/PYL receptor polypeptide inhibits the PP2C in the absence of ABA or an ABA agonist.
 2. The expression cassette of claim 1, wherein the mutated PYR/PYL receptor polypeptide further comprises an amino acid substitution at one or more dimer interface positions selected from positions F61, K63, I84, S85, L87, P88, A89, S152, D155, T156, M158, F159, T162, L166, and K170, wherein the positions are numbered with reference to SEQ ID NO:89.
 3. The expression cassette of claim 1, wherein the mutated PYR/PYL receptor polypeptide comprises a H60P substitution.
 4. The expression cassette of claim 2, wherein the constitutively active PYR/PYL receptor polypeptide comprises an amino acid substitution at position M158.
 5. The expression cassette of claim 4, wherein the constitutively active PYR/PYL receptor polypeptide comprises a M158I, M158T, or M158V substitution.
 6. The expression cassette of claim 1, wherein the promoter is tissue-specific or inducible.
 7. The expression cassette of claim 1, wherein a plant into which the expression cassette is introduced has improved stress tolerance compared to a plant lacking the expression cassette.
 8. The expression cassette of claim 7, wherein a plant into which the expression cassette is introduced has improved drought tolerance compared to a plant lacking the expression cassette.
 9. An expression vector comprising the expression cassette of claim
 1. 10. A method of making a plant with increased stress tolerance, the method comprising: introducing the expression cassette of claim 1 into a plurality of plants; and selecting a plant comprising the expression cassette having increased stress tolerance compared to a plant lacking the expression cassette.
 11. A plant comprising a heterologous expression cassette, the expression cassette comprising a heterologous promoter operably linked to a polynucleotide encoding a mutated PYR/PYL receptor polypeptide, wherein the mutated PYR/PYL, receptor polypeptide is at least 90% identical to any of SEQ ID NO:85, SEQ ID NO:87, SEQ ID NO:88, SEQ ID NO:89, or SEQ ID NO:90 and further comprises an amino acid substitution, relative to a naturally-occurring PYR/PYL receptor polypeptide, at position H60 as numbered with reference to SEQ ID NO:89, wherein the naturally-occurring PYR/PYL receptor polypeptide does not inhibit a type 2 protein phosphatase (PP2C) in the absence of abscisic acid (ABA) and wherein the mutated PYR/PYL receptor polypeptide inhibits the PP2C in the absence of ABA or an ABA agonist.
 12. The plant of claim 11, wherein the mutated PYR/PYL receptor polypeptide further comprises an amino acid substitution at one or more dimer interface positions selected from positions F61, K63, I84, S85, L87, P88, A89, S152, D155, T156, M158, F159, T162, L166, and K170, wherein the positions are numbered with reference to SEQ ID NO:89.
 13. The plant of claim 11, wherein the mutated PYR/PYL receptor polypeptide comprises a H60P substitution.
 14. The plant of claim 12, wherein the constitutively active PYR/PYL receptor polypeptide comprises an amino acid substitution at position M158.
 15. The plant of claim 14, wherein the constitutively active PYR/PYL receptor polypeptide comprises a M158I, M158T, or M158V substitution.
 16. The plant of claim 11, wherein the plant has improved stress tolerance compared to a plant lacking the expression cassette.
 17. The plant of claim 16, wherein the plant has improved drought tolerance compared to a plant lacking the expression cassette.
 18. The plant of claim 11, wherein the promoter is tissue-specific or inducible.
 19. A plant cell from the plant of claim
 11. 20. A seed, flower, leaf or fruit from the plant of claim 11 comprising the heterologous expression cassette.
 21. The expression cassette of claim 1, wherein the mutated PYR/PYL receptor polypeptide is at least 95% identical to any of SEQ ID NO:85, SEQ ID NO:87, SEQ ID NO:88, SEQ ID NO:89, or SEQ ID NO:90.
 22. The plant of claim 11, wherein the mutated PYR/PYL receptor polypeptide is at least 95% identical to any of SEQ ID NO:85, SEQ ID NO:87, SEQ ID NO:88, SEQ ID NO:89, or SEQ ID NO:90. 